The process of finding chemicals for potential therapeutic use.
The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.
Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.
Large collections of small molecules (molecular weight about 600 or less), of similar or diverse nature which are used for high-throughput screening analysis of the gene function, protein interaction, cellular processing, biochemical pathways, or other chemical interactions.
Rapid methods of measuring the effects of an agent in a biological or chemical assay. The assay usually involves some form of automation or a way to conduct multiple assays at the same time using sample arrays.
Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.
Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.
That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.
Databases devoted to knowledge about PHARMACEUTICAL PRODUCTS.
A technology, in which sets of reactions for solution or solid-phase synthesis, is used to create molecular libraries for analysis of compounds on a large scale.
The deliberate and methodical practice of finding new applications for existing drugs.
Databases devoted to knowledge about specific chemicals.
Dynamic and kinetic mechanisms of exogenous chemical and DRUG LIBERATION; ABSORPTION; BIOLOGICAL TRANSPORT; TISSUE DISTRIBUTION; BIOTRANSFORMATION; elimination; and DRUG TOXICITY as a function of dosage, and rate of METABOLISM. LADMER, ADME and ADMET are abbreviations for liberation, absorption, distribution, metabolism, elimination, and toxicology.
The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds.
The study of the origin, nature, properties, and actions of drugs and their effects on living organisms.
A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed)
A quantitative prediction of the biological, ecotoxicological or pharmaceutical activity of a molecule. It is based upon structure and activity information gathered from a series of similar compounds.
Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.
A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252)
Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures.
The application of scientific knowledge or technology to pharmacy and the pharmaceutical industry. It includes methods, techniques, and instrumentation in the manufacture, preparation, compounding, dispensing, packaging, and storing of drugs and other preparations used in diagnostic and determinative procedures, and in the treatment of patients.
A field of biology concerned with the development of techniques for the collection and manipulation of biological data, and the use of such data to make biological discoveries or predictions. This field encompasses all computational methods and theories for solving biological problems including manipulation of models and datasets.
Diseases that are underfunded and have low name recognition but are major burdens in less developed countries. The World Health Organization has designated six tropical infectious diseases as being neglected in industrialized countries that are endemic in many developing countries (HELMINTHIASIS; LEPROSY; LYMPHATIC FILARIASIS; ONCHOCERCIASIS; SCHISTOSOMIASIS; and TRACHOMA).
Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.
The use of computers for designing and/or manufacturing of anything, including drugs, surgical procedures, orthotics, and prosthetics.
Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.
The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.
The science of drugs prepared from natural-sources including preparations from PLANTS, animals, and other organisms as well as MINERALS and other substances included in MATERIA MEDICA. The therapeutic usage of plants is PHYTOTHERAPY.
A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task.
The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture.
Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.
The systematic study of the complete DNA sequences (GENOME) of organisms.
Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein.
Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
Sequential operating programs and data which instruct the functioning of a digital computer.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans.
A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein.
The parts of a macromolecule that directly participate in its specific combination with another molecule.
The field of information science concerned with the analysis and dissemination of data through the application of computers.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The systematic study of the complete complement of proteins (PROTEOME) of organisms.
The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Substances that inhibit or prevent the proliferation of NEOPLASMS.
The largest family of cell surface receptors involved in SIGNAL TRANSDUCTION. They share a common structure and signal through HETEROTRIMERIC G-PROTEINS.
Infections with the protozoa of the phylum EUGLENOZOA.
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
Comprehensive, methodical analysis of complex biological systems by monitoring responses to perturbations of biological processes. Large scale, computerized collection and analysis of the data are used to develop and test models of biological systems.
Computer-based representation of physical systems and phenomena such as chemical processes.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.
A branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (BIOTRANSFORMATION).
Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
Time period from 1901 through 2000 of the common era.
Drugs used to treat or prevent parasitic infections.
A social science dealing with group relationships, patterns of collective behavior, and social organization.
The study of the physical and chemical properties of a drug and its dosage form as related to the onset, duration, and intensity of its action.
A collection of cloned peptides, or chemically synthesized peptides, frequently consisting of all possible combinations of amino acids making up an n-amino acid peptide.
A method of measuring the effects of a biologically active substance using an intermediate in vivo or in vitro tissue or cell model under controlled conditions. It includes virulence studies in animal fetuses in utero, mouse convulsion bioassay of insulin, quantitation of tumor-initiator systems in mouse skin, calculation of potentiating effects of a hormonal factor in an isolated strip of contracting stomach muscle, etc.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
A site on an enzyme which upon binding of a modulator, causes the enzyme to undergo a conformational change that may alter its catalytic or binding properties.
The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain).
Controlled operations of analytic or diagnostic processes, or systems by mechanical or electronic devices.
Organizations representing specialized fields which are accepted as authoritative; may be non-governmental, university or an independent research organization, e.g., National Academy of Sciences, Brookings Institution, etc.
Property, such as patents, trademarks, and copyright, that results from creative effort. The Patent and Copyright Clause (Art. 1, Sec. 8, cl. 8) of the United States Constitution provides for promoting the progress of science and useful arts by securing for limited times to authors and inventors, the exclusive right to their respective writings and discoveries. (From Black's Law Dictionary, 5th ed, p1014)
Tests that demonstrate the relative effectiveness of chemotherapeutic agents against specific parasites.
The branch of pharmacology dealing especially with the action of drugs upon various parts of the nervous system.
The portion of an interactive computer program that issues messages to and receives commands from a user.
An analytical method used in determining the identity of a chemical based on its mass using mass analyzers/mass spectrometers.
The study of the actions and properties of medicinal agents, often derived from PLANTS, indigenous to populations or ETHNIC GROUPS.
An array of tests used to determine the toxicity of a substance to living systems. These include tests on clinical drugs, foods, and environmental pollutants.
Controlled operation of an apparatus, process, or system by mechanical or electronic devices that take the place of human organs of observation, effort, and decision. (From Webster's Collegiate Dictionary, 1993)
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585)
A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.
Cells from adult organisms that have been reprogrammed into a pluripotential state similar to that of EMBRYONIC STEM CELLS.
Extensive collections, reputedly complete, of facts and data garnered from material of a specialized subject area and made available for analysis and application. The collection can be automated by various contemporary methods for retrieval. The concept should be differentiated from DATABASES, BIBLIOGRAPHIC which is restricted to collections of bibliographic references.
Methods for determining interaction between PROTEINS.
Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., GENETIC ENGINEERING) is a central focus; laboratory methods used include TRANSFECTION and CLONING technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction.
A multistage process that includes cloning, physical mapping, subcloning, determination of the DNA SEQUENCE, and information analysis.
Databases containing information about PROTEINS such as AMINO ACID SEQUENCE; PROTEIN CONFORMATION; and other properties.
Use of sophisticated analysis tools to sort through, organize, examine, and combine large sets of information.
The characteristic three-dimensional shape of a molecule.
Manufacturing technology for making microscopic devices in the micrometer range (typically 1-100 micrometers), such as integrated circuits or MEMS. The process usually involves replication and parallel fabrication of hundreds or millions of identical structures using various thin film deposition techniques and carried out in environmentally-controlled clean rooms.
Time period from 2001 through 2100 of the common era.
Theoretical representations that simulate the behavior or activity of chemical processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
The metabolism of drugs and their mechanisms of action.
Cells derived from the BLASTOCYST INNER CELL MASS which forms before implantation in the uterine wall. They retain the ability to divide, proliferate and provide progenitor cells that can differentiate into specialized cells.
Critical and exhaustive investigation or experimentation, having for its aim the discovery of new facts and their correct interpretation, the revision of accepted conclusions, theories, or laws in the light of newly discovered facts, or the practical application of such new or revised conclusions, theories, or laws. (Webster, 3d ed)
The use of DRUGS to treat a DISEASE or its symptoms. One example is the use of ANTINEOPLASTIC AGENTS to treat CANCER.
The application of discoveries generated by laboratory research and preclinical studies to the development of clinical trials and studies in humans. A second area of translational research concerns enhancing the adoption of best practices.
Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.
Luciferases from FIREFLIES, usually Photinus, that oxidizes FIREFLY LUCIFERIN to cause emission of PHOTONS.
A set of statistical methods used to group variables or observations into strongly inter-related subgroups. In epidemiology, it may be used to analyze a closely grouped series of events or cases of disease or other health-related phenomenon with well-defined distribution patterns in relation to time or place or both.
A cell line derived from cultured tumor cells.
A subfield of psychiatry that emphasizes the somatic substructure on which mental operations and emotions are based, and the functional or organic disturbances of the central nervous system that give rise to, contribute to, or are associated with mental and emotional disorders. (From Campbell's Psychiatric Dictionary, 8th ed.)
Agents that inhibit PROTEIN KINASES.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Plants whose roots, leaves, seeds, bark, or other constituent parts possess therapeutic, tonic, purgative, curative or other pharmacologic attributes, when administered to man or animals.
Therapeutic approach tailoring therapy for genetically defined subgroups of patients.
A computer simulation developed to study the motion of molecules over a period of time.
The modification of the reactivity of ENZYMES by the binding of effectors to sites (ALLOSTERIC SITES) on the enzymes other than the substrate BINDING SITES.
Substances that reduce the growth or reproduction of BACTERIA.
Established cell cultures that have the potential to propagate indefinitely.
Mixtures of many components in inexact proportions, usually natural, such as PLANT EXTRACTS; VENOMS; and MANURE. These are distinguished from DRUG COMBINATIONS which have only a few components in definite proportions.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts.
A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.
Databases devoted to knowledge about specific genes and gene products.
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
The protein complement of an organism coded for by its genome.
Compounds that specifically inhibit STEROL 14-DEMETHYLASE. A variety of azole-derived ANTIFUNGAL AGENTS act through this mechanism.
The study of the structure, behavior, growth, reproduction, and pathology of cells; and the function and chemistry of cellular components.
Compounds that inhibit or prevent the proliferation of CELLS.
Theory and development of COMPUTER SYSTEMS which perform tasks that normally require human intelligence. Such tasks may include speech recognition, LEARNING; VISUAL PERCEPTION; MATHEMATICAL COMPUTING; reasoning, PROBLEM SOLVING, DECISION-MAKING, and translation of language.
Research that involves the application of the natural sciences, especially biology and physiology, to medicine.
Complex sets of enzymatic reactions connected to each other via their product and substrate metabolites.
The science concerned with the detection, chemical composition, and biological action of toxic substances or poisons and the treatment and prevention of toxic manifestations.
The complete genetic complement contained in the DNA of a set of CHROMOSOMES in a HUMAN. The length of the human genome is about 3 billion base pairs.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
ANESTHESIA achieved by lowering either BODY TEMPERATURE (core cooling) or SKIN TEMPERATURE (external cooling).
Drug agonism involving selective binding but reduced effect. This can result in some degree of DRUG ANTAGONISM.
The level of protein structure in which combinations of secondary protein structures (alpha helices, beta sheets, loop regions, and motifs) pack together to form folded shapes called domains. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Small proteins usually consist of only one domain but larger proteins may contain a number of domains connected by segments of polypeptide chain which lack regular secondary structure.
The study of medicines derived from botanical sources.
Proteins found in any species of bacterium.
Substances that are destructive to protozoans.
A genus of protozoa that comprise the malaria parasites of mammals. Four species infect humans (although occasional infections with primate malarias may occur). These are PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PLASMODIUM OVALE, and PLASMODIUM VIVAX. Species causing infection in vertebrates other than man include: PLASMODIUM BERGHEI; PLASMODIUM CHABAUDI; P. vinckei, and PLASMODIUM YOELII in rodents; P. brasilianum, PLASMODIUM CYNOMOLGI; and PLASMODIUM KNOWLESI in monkeys; and PLASMODIUM GALLINACEUM in chickens.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)
The region of an enzyme that interacts with its substrate to cause the enzymatic reaction.
Experimentation on STEM CELLS and on the use of stem cells.
Measurable biological parameters that serve for drug development, safety and dosing (DRUG MONITORING).
Collections of facts, assumptions, beliefs, and heuristics that are used in combination with databases to achieve desired results, such as a diagnosis, an interpretation, or a solution to a problem (From McGraw Hill Dictionary of Scientific and Technical Terms, 6th ed).
Societies whose membership is limited to pharmacists.
Compounds that are designed to mimic the 3D structure of a natural peptide or protein.
A mass spectrometry technique using two (MS/MS) or more mass analyzers. With two in tandem, the precursor ions are mass-selected by a first mass analyzer, and focused into a collision region where they are then fragmented into product ions which are then characterized by a second mass analyzer. A variety of techniques are used to separate the compounds, ionize them, and introduce them to the first mass analyzer. For example, for in GC-MS/MS, GAS CHROMATOGRAPHY-MASS SPECTROMETRY is involved in separating relatively small compounds by GAS CHROMATOGRAPHY prior to injecting them into an ionization chamber for the mass selection.
A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation.
Biological activities of viruses and their interactions with the cells they infect.
Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
The arrangement of two or more amino acid or base sequences from an organism or organisms in such a way as to align areas of the sequences sharing common properties. The degree of relatedness or homology between the sequences is predicted computationally or statistically based on weights assigned to the elements aligned between the sequences. This in turn can serve as a potential indicator of the genetic relatedness between the organisms.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
A technique encompassing morphometry, densitometry, neural networks, and expert systems that has numerous clinical and research applications and is particularly useful in anatomic pathology for the study of malignant lesions. The most common current application of image cytometry is for DNA analysis, followed by quantitation of immunohistochemical staining.
Any of a variety of procedures which use biomolecular probes to measure the presence or concentration of biological molecules, biological structures, microorganisms, etc., by translating a biochemical interaction at the probe surface into a quantifiable physical signal.
Chromatographic techniques in which the mobile phase is a liquid.
The application of engineering principles and methods to living organisms or biological systems.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
An exotic species of the family CYPRINIDAE, originally from Asia, that has been introduced in North America. They are used in embryological studies and to study the effects of certain chemicals on development.
Methods for maintaining or growing CELLS in vitro.
An interdisciplinary field in materials science, ENGINEERING, and BIOLOGY, studying the use of biological principles for synthesis or fabrication of BIOMIMETIC MATERIALS.
The relationships of groups of organisms as reflected by their genetic makeup.
Graphs representing sets of measurable, non-covalent physical contacts with specific PROTEINS in living organisms or in cells.
Time period from 1801 through 1900 of the common era.
A specialty concerned with the nature and cause of disease as expressed by changes in cellular or tissue structure and function caused by the disease process.
Methods utilizing the principles of MICROFLUIDICS for sample handling, reagent mixing, and separation and detection of specific components in fluids.
The scientific disciplines concerned with the embryology, anatomy, physiology, biochemistry, pharmacology, etc., of the nervous system.
A group of atoms or molecules attached to other molecules or cellular structures and used in studying the properties of these molecules and structures. Radioactive DNA or RNA sequences are used in MOLECULAR GENETICS to detect the presence of a complementary sequence by NUCLEIC ACID HYBRIDIZATION.
A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics.
A large collection of DNA fragments cloned (CLONING, MOLECULAR) from a given organism, tissue, organ, or cell type. It may contain complete genomic sequences (GENOMIC LIBRARY) or complementary DNA sequences, the latter being formed from messenger RNA and lacking intron sequences.
Ligand-binding assays that measure protein-protein, protein-small molecule, or protein-nucleic acid interactions using a very large set of capturing molecules, i.e., those attached separately on a solid support, to measure the presence or interaction of target molecules in the sample.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.

A Fourier transformation based method to mine peptide space for antimicrobial activity. (1/2214)

BACKGROUND: Naturally occurring antimicrobial peptides are currently being explored as potential candidate peptide drugs. Since antimicrobial peptides are part of the innate immune system of every living organism, it is possible to discover new candidate peptides using the available genomic and proteomic data. High throughput computational techniques could also be used to virtually scan the entire peptide space for discovering out new candidate antimicrobial peptides. RESULT: We have identified a unique indexing method based on biologically distinct characteristic features of known antimicrobial peptides. Analysis of the entries in the antimicrobial peptide databases, based on our indexing method, using Fourier transformation technique revealed a distinct peak in their power spectrum. We have developed a method to mine the genomic and proteomic data, for the presence of peptides with potential antimicrobial activity, by looking for this distinct peak. We also used the Euclidean metric to rank the potential antimicrobial peptides activity. We have parallelized our method so that virtually any given protein space could be data mined, in search of antimicrobial peptides. CONCLUSION: The results show that the Fourier transform based method with the property based coding strategy could be used to scan the peptide space for discovering new potential antimicrobial peptides.  (+info)

A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. (2/2214)

BACKGROUND: Drug treatment is becoming more expensive due to the increased cost for the introduction of new drugs, and there seems to be an uneven distribution of medication cost for different therapeutic categories. We hypothesized that the cost of new antimicrobial agents may differ from that of other therapeutic categories and this may play a role in the stagnation of development of new antibiotics. METHODOLOGY/PRINCIPAL FINDINGS: We performed a pharmaco-economical comparative analysis of the drug cost of treatment for new agents introduced in the United States drug market in various therapeutic categories. We calculated the drug cost (in US dollars) of a ten-day treatment of all new drugs approved by the FDA during the period between January 1997 and July 2003, according to the 2004 Red Book Pharmacy's Fundamental Reference. New anti-neoplastic agents were found to be the most expensive drugs in comparison to all other therapeutic categories, with a median ten-day drug-treatment cost of US$848 compared to the median ten-day drug-treatment costs of all other categories ranging from US$29 to US$301. On the other hand, new antimicrobial drugs were found to be much less expensive, with a median ten-day drug-treatment cost of US$137 and $US85 for all anti-microbial agents and for anti-microbial agents excluding anti-HIV medications, respectively. CONCLUSIONS/SIGNIFICANCE: The drug-treatment cost of new medications varies considerably by different therapeutic categories. This fact may influence industry decisions regarding the development of new drugs and may play a role in the shortage of new antimicrobial agents in the fight against the serious problem of antimicrobial resistance.  (+info)

Hydrogen sulfide: third gaseous transmitter, but with great pharmacological potential. (3/2214)

Hydrogen sulfide (H2S), which is well known traditionally as a toxic gas, has been proven to be produced endogenously by 3 enzymes in mammalian tissues and plays important roles in physiological and pathophysiological conditions. In the central nervous system, H2S functions as not only a neuromodulator, but also a neuroprotectant against oxidative stress. In the cardiovascular system, H2S relaxes vascular smooth muscles by the activation of KATP channels and inhibits smooth muscle cell proliferation via the mitogen-activated protein kinase signaling pathway. These effects are important for maintaining blood pressure and preventing vessel structural remodeling, and identifies H2S as an important factor in the development of some vascular diseases, such as hypertension. H2S also shows cardioprotective effects in ischemic myocardium and septic and endotoxin shock. Recent studies have demonstrated a new mechanism to explain the motor effect of H2S on the rat detrusor muscle, which is through the activation of the capsaicin-sensitive primary neuron. This review focuses on the recent research achievements on H2S and discloses the great potential of H2S as the third gaseous transmitter in cardiac protection.  (+info)

Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases. (4/2214)


Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors. (5/2214)

The near universal presence of EBV in certain tumors suggests that new EBV-based therapies could be developed for these malignancies. We have explored one EBV-based therapy that involves the purposeful induction of lytic EBV infection in tumors. Induction of lytic EBV infection in tumors activates expression of EBV-encoded kinases that convert the prodrug, ganciclovir, to its active cytotoxic form. In mouse models for EBV-positive tumors, the combination of lytic-inducing chemotherapy and ganciclovir is much more effective than either agent alone for treating tumors. Another potential EBV-based target is the cellular protein, CD70. EBV-positive tumors commonly express CD70, while CD70 expression in normal cells is restricted to a few highly activated B cells and T cells. Anti-CD70 monoclonal antibody inhibits the growth of CD70-positive (but not CD70-negative) Burkitt's lymphomas in SCID mice. Finally, while completely lytic EBV infection is clearly incompatible with tumor cell growth, we recently discovered that small numbers of lytically-infected cells actually promote the growth of EBV-immortalized lymphocytes in SCID mice, through the release of paracrine growth factors as well as angiogenic factors. Thus, agents that prevent the earliest stage of lytic EBV infection (such as fatty acid synthase inhibitors), rather than the later stage of viral replication, might also be useful in the treatment of early-stage EBV-positive tumors.  (+info)

Characterization of mitochondrial trifunctional protein and its inactivation study for medicine development. (6/2214)


Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care. (7/2214)


The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. (8/2214)


The aim of the 6th RSC-BMCS Fragment-based Drug Discovery meeting will be to continue the focus on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programmes. The Fragment series was started in 2007 and continues with the theme, having over three-quarters of the presentations focused on case studies. The conference will include successful examples from all types of fragment-based approaches, including high concentration, NMR, SPR and X-ray screening ...
TY - CHAP. T1 - Fragment-based drug discovery in academia. T2 - Experiences from a tuberculosis programme. AU - Heikkila, T.J.. AU - Surade, S.. AU - Silvestre, H.L.. AU - Dias, M.V.B.. AU - Ciulli, A.. AU - Bromfield, K.. AU - Scott, D.. AU - Howard, N.. AU - Wen, S.. AU - Wei, A.H.. AU - Osborne, D.. AU - Abell, C.. AU - Blundell, T.L.. PY - 2009. Y1 - 2009. N2 - The problems associated with neglected diseases are often compounded by increasing incidence of antibiotic resistance. Patient negligence and abuse of antibiotics has lead to explosive growth in cases of tuberculosis, with some M. tuberculosis strains becoming virtually untreatable. Structure-based drug development is viewed as cost-effective and time-consuming method for discovery and development of hits to lead compounds. In this review we will discuss the suitability of fragment-based methods for developing new chemotherapeutics against neglected diseases, providing examples from our tuberculosis programme.. AB - The problems ... Fragment screening services and fragment optimization collectively form the fragment-based drug discovery market. Fragment screening segment was further segmented into biophysical services and non-biophysical services. Biophysical services are further segmented into techniques such as Nuclear Magnetic Resonance (NMR) Spectroscopy, Differential scanning Fluorimetry (DSF) Assay (Thermal Shift), Fluorescence Polarization (FP), Isothermal Titration Calorimetry (ITC), X-ray Crystallography, Surface Plasmon Resonance, Biolayer Interferometry, Mass Spectrometry, Capillary Electrophoresis, and others (biochemical assays). NMR was the largest segment of the FBDD market, accounting for approximately 19.7% share in 2014. The technique is expected to maintain its leadership position during the forecast period. Advantages of NMR such as high reliability, easy operability, and wide versatility are likely to fuel ...
D. A. Erlanson Introduction to Fragment-Based Drug Discovery T. G. Davies Ian J. Tickle Fragment Screening Using X-Ray Crystallography S. Roughley L. Wright P. Brough A. Massey R. E. Hubbard Hsp90 Inh
BALTIMORE, June 30, 2017 /PRNewswire/ -- AgeneBio Receives Grant from Alzheimers Drug Discovery Foundation for Drug-Discovery Program to Delay the Onset of Alzheimers Dementia. Novel GABA-A program targets hippocampal overactivity that leads to neurodegeneration and cognitive decline in Alzheimers disease patients.
Fragment-based drug discovery is an emerging process that has gained popularity in recent years. The process starts from small molecules called fragments. One major step in fragment-based drug discovery is fragment screening, which is a strategy to screen libraries of small molecules to find hits. The strategy in theory is more efficient than traditional high-throughput screening that works with larger molecules. As fragments intrinsically possess weak affinity to a target, detection techniques of high sensitivity to affinity are required for fragment screening. Furthermore, the use of different screening methods is necessary to improve the likelihood of success in finding suitable fragments. Since no single method can work for all types of screening, there is a demand for new techniques. The aim of this thesis is to introduce weak affinity chromatography (WAC) as a novel technique for fragment screening.. WAC is, as the name suggests, an affinity-based liquid chromatographic technique that ...
The conjugation of the small ubiquitin-like modifier (SUMO) to protein substrates is an important post-translational modification that has ramifications for cancer and other diseases. As the sole E2 enzyme in the tightly regulated E1/E2/E3 SUMOylation enzymatic cascade, Ubc9 plays a central role in the conjugation of all three SUMO isoforms to a variety of protein targets. Although Ubc9 is viewed as a promising anti-cancer drug target, the development of small-molecule Ubc9 inhibitors has proven to be very difficult. In the past decade, fragment-based drug design has emerged as a powerful approach to identify ligands for challenging protein targets that can provide excellent starting points for the development of potent inhibitors. By X-ray crystallographic fragment screening, we have identified two small-molecule fragments that bind to Ubc9 at a location that is distal from its active site. Although these fragments have weak affinity for Ubc9, biochemical assays have confirmed that they inhibit ...
REVISED APPLICATION RECEIPT DATE: NATIONAL COOPERATIVE DRUG DISCOVERY RESEARCH ON OPPORTUNISTIC INFECTIONS Release Date: October 8, 1998 PA NUMBER: PA-98-100 P.T. National Institute of Allergy and Infectious Diseases National Cancer Institute Application Receipt Date: January 20, 1999 PURPOSE PA-98-100, NATIONAL COOPERATIVE DRUG DISCOVERY RESEARCH ON OPPORTUNISTIC INFECTIONS, appeared in the NIH Guide on August 25, 1998. The application receipt date in that program announcement was November 19, 1998. In order to provide applicants with more time to prepare their applications for research project (R01) grants, the receipt date for applications has been extended to January 20, 1999. INQUIRIES Written and telephone inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Barbara Laughon, Ph.D. Division of AIDS National Institute of Allergy and Infectious Diseases 6003 Executive Boulevard, Room 2C26 - MSC 7620 Bethesda, MD 20892-7620 ...
World Congress on Drug discovery & Development -2016, Indian Institute of Science, Jul 18-20, 2016, Bangalore, Karnataka. Browse other events at Indian Institute of Science, Bangalore
High-throughput screening remains one of the most powerful, unbiased approaches for small molecule drug discovery.. Today, the toolbox for high-throughput screening features traditional label-dependent approaches and novel label-free technologies. Researchers determine which methodology offers the most promising path forward for their target, taking into account assay sensitivity, data quality, costs, and speed. Moreover, many companies opt to outsource drug discovery efforts to contract research organizations, which offer a particular expertise and an established discovery infrastructure to lead hit identification and hit-to-lead programs.. In this white paper, we discuss important aspects to consider when choosing a methodology for drug discovery. ...
After 20 years of sometimes quiet growth, fragment-based drug discovery (FBDD) has become mainstream. More than 30 drug candidates derived from fragments have entered the clinic, with two approved and several more in advanced trials. FBDD has been widely applied in both academia and industry, as evi …
The reason for the low number of successful new CNS drugs is the subject of debate, although it is undoubtedly related to their higher attrition rate during development, particularly from issues related to failures of on-target biological hypotheses. To address this problem, there has been a recent emphasis on research to tackle these issues at an earlier stage in the drug discovery pathway. In particular, there has been increased interest in target discovery both for the identification of novel targets and reducing the subsequent failure from incorrect biological hypotheses through early validation.. Target discovery, which involves the identification and early validation of disease-modifying targets, is an essential first step in the drug discovery process. Furthermore, although the knowledge of the target for a small molecule drug is not required by the FDA for drug development, it is crucial information if the drug discovery process is to be made more efficient and effective. Identifying the ...
TY - JOUR. T1 - Semantic text mining in early drug discovery for type 2 diabetes. AU - Hansson, Lena K.. AU - Hansen, Rasmus Borup. AU - Pletscher-Frankild, Sune. AU - Berzins, Rudolfs. AU - Hansen, Daniel Hvidberg. AU - Madsen, Dennis. AU - Christensen, Sten B.. AU - Revsbech Christiansen, Malene. AU - Boulund, Ulrika. AU - Wolf, Xenia Asbæk. AU - Kjærulff, Sonny Kim. AU - van de Bunt, Martijn. AU - Tulin, Søren. AU - Jensen, Thomas Skøt. AU - Wernersson, Rasmus. AU - Jensen, Jan Nygaard. PY - 2020. Y1 - 2020. N2 - BACKGROUND: Surveying the scientific literature is an important part of early drug discovery; and with the ever-increasing amount of biomedical publications it is imperative to focus on the most interesting articles. Here we present a project that highlights new understanding (e.g. recently discovered modes of action) and identifies potential drug targets, via a novel, data-driven text mining approach to score type 2 diabetes (T2D) relevance. We focused on monitoring trends and ...
Jim Wells (UCSF) gave a magisterial keynote address that emphasized how useful fragments can be for tackling difficult targets such as protein-protein interactions (PPIs). In fact, many of the talks in the protein-protein interaction track relied on fragments. Thats not to say its easy. Rod Hubbard (University of York and Vernalis) emphasized that advancing fragments to leads against such targets can take a long time and often requires patience that strains the management of many organizations. Fragment hits against PPIs usually have lower ligand efficiencies (0.23-0.25 kcal/mol/HA if youre lucky), and improving potency can be a bear. Rhian Holvey (University of Cambridge) presented a nice example of how she was able to find millimolar fragments that bind to the anti-mitotic target TPX2, potentially blocking its interaction with importin-alpha, but even structural information was not enough to get to potent inhibitors ...
One theme throughout the conference was the observation that fragments bind at multiple sites on proteins. Harren noted that Astex researchers have found fragments bound (crystallographically) to 54 sites on 25 targets - an average of 2.2 sites per target. Some targets are even more site-rich: Joe Patel (AstraZeneca) performed a crystallographic screen on a complex of Ras and SOS and found four binding sites, including one previously discussed here. In this effort, 1200 fragments were screened in pools of 4, and in one case two fragments from the same pool each bound only when they were both present at the same time - each fragment alone showed no binding by NMR or crystallography ...
The Selcia Fragment Library is available in conjunction with its CEfrag™ screening service and consists of approximately 1400 compounds.
Chris is a leader in pharmaceutical research with expertise in fragment-based drug discovery, structure-based drug design, target analysis, kinases, phosphodiesterases, nuclear hormone receptors, and proteases. In his current role, as Associate Director of Structural Biology at Astra Zeneca, he is leading a team of scientists supporting pipeline projects with structural insights.. In his previous role as a senior principal scientist at Pfizer for over 13 years, he developed the core capabilities in macromolecular crystallography with emphasis on the application of structural information in the drug discovery process. Chris acquired a D. Phil in macromolecular crystallography and was also a postdoctoral research associate at the University of Oxford.. Chris has been an enthusiastic contributor and strong supporter of the Cambridge Pharmaceutical Consortium. The consortium has brought together pharmaceutical companies, the University of Cambridge, the Medical Research Councils Laboratory of ...
ZoBio offers Fragment-Based Drug Discovery research services on a fee-for-service basis to customers across the pharmaceutical & biotechnology industries.
ZoBio offers Fragment-Based Drug Discovery research services on a fee-for-service basis to customers across the pharmaceutical & biotechnology industries.
In 2009, the same development team created Adam, a robot scientist that became the first machine to independently discover new scientific knowledge. They used the knowledge from that experiment to create Eve with the purpose of speeding up the drug discovery process and make it more economical. In the published study, the researchers discuss describe how the robot is able to identify promising new drug candidates for malaria and other neglected tropical diseases, such as African sleeping sickness and Chagas disease.. Neglected tropical diseases are a scourge of humanity, infecting hundreds of millions of people, and killing millions of people every year, said Steve Oliver, a professor from the Cambridge Systems Biology Centre and the Department of Biochemistry at the University of Cambridge. We know what causes these diseases and that we can, in theory, attack the parasites that cause them using small molecule drugs. But the cost and speed of drug discovery and the economic return make them ...
Novartis Institutes for BioMedical Research, Cambridge, USA. Affinity proteomics and target identification for small molecule drug candidates. Affinity proteomics has become a valuable tool in preclinical small molecule drug discovery, in particular in the context of target identification and elucidation of the mechanism of action for drug candidates from phenotypic and pathway-centric approaches to drug discovery. Quantitative chemoproteomics, employing variations of a competition-based approach to small molecule affinity chromatography and mass spectrometry-based protein identification and quantitation, identifies cellular protein interactors and thus potential targets of drug candidates under conditions approximating the disease-relevant in vivo situation. Several examples will be presented and discussed in the context of orthogonal approaches to the generation of target hypotheses. On the other hand, the identification of protein-protein interactions using e.g. an affinity-tagged bait ...
The University of Michigan Center for the Discovery of New Medicines has awarded early-stage funding for seven new drug discovery projects by faculty from across U-M. Six of the projects focus on treating disease including heart failure, runaway cell division in cancer, hypertension, Crohns disease, a genetic heart disorder and neurological damage. The deadline for the next round of grant proposals is April 20. Learn more and apply.
By Rich Soll, SVP of Research Service Division at WuXi AppTec (@richsollwx). From developing new paradigms for early-stage drug discovery for rare and common diseases to fostering the convergence of peptide nanotechnology, and launching scientific experiments in space, Israeli biochemist Ehud Gazit is wearing many hats these days.. In his role as academic director at the newly-formed Blavatnik Center for Drug Discovery (BCDD) at Tel Aviv University in Israel, Gazit is leading efforts to provide the missing link that may enable many scientific discoveries to evolve into beneficial drugs. The Center is uniquely dedicated to translational science by helping researchers turn their discoveries into effective pharmaceuticals.. Gazit - also a biophysicist and nanotechnologist - stays active in his university lab, which explores biological and bio-inspired molecular self-assembly. The lab studies the organization of biological systems in diverse fields, including amyloid diseases, diabetes, virology, ...
Drug Discovery Today is a review journal, published as monthly 12 double issues. The journal covers the whole of the preclinical drug discovery process, from target identification and validation, through hit identification, lead identification and optimisation, though to candidate selection. The reviews are at the cutting edge of the science underpinning drug discovery, written by experts in their respective fields and cover all aspects of drug discovery from state-of-the-art genomic and proteomic approaches to target identification, through the most innovative computational approaches drug design, the science driving medicinal chemistry and the translation of these sciences to therapies
3rd Drug Discovery Re-Invented Conference is organized between 21 Feb and 24 Feb 2017. The Conference venue is Fiesta Americana Condesa in Cancun, Mexico. It will be a trend-setting Conference, illustrious as one of the most inventive meetings within the Medical, Pharmacology, Pharmaceutical, Drug Development, Biotechnology, Biosciences and Natural Products aspects. 3rd Drug Discovery Re-Invented Conference is once Conference. The organizer of the Drug Discovery Re-Invented 2017, 3rd Drug Discovery Re-Invented Conference is Fusion Conferences Limited. Let Cancun must do holiday attractions make you fall in love with this city when you are there for Drug Discovery Re-Invented 2017. Here are top notch things to do in Cancun ...
It aims to bring together leading academic researchers and research scholars to exchange and share their experiences and research results on all aspects of Drug Discovery, Designing and Development. It also provides a premier interdisciplinary platform for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns as well as practical challenges encountered and solutions adopted in the fields of Drug Discovery, Designing and Development ...
Scientists demonstrate new method of producing a specific class of organic compounds, which promises to accelerate drug discovery research for several diseases.. Several drugs, including those for depression, schizophrenia, and malaria, would not be if not for a type of organic chemical compound called alicyclic compounds. These compounds are 3D structures formed when three or more carbon atoms join in a ring via covalent bonds, but the ring is not aromatic.. Aromatic compounds (or arenes) are another class of organic compounds which are 2D structures with reactive properties distinct from those of alicyclic compounds. A well-known example is benzene, the six-carbon ring comprising alternating single- and double-bonds between the carbon atoms.. By dearomatizing arenes, one can get alicyclic compounds. In fact, this dearomatization is one of the most powerful ways of obtaining alicyclic compounds. But some of the most abundantly available arenes, such as benzene and naphthalene, are very stable, ...
The original iPS methods employed retroviruses to introduce the four cDNAs into cells7,8. Until recently, the majority of methods have relied on viral introduction of one form or another - a technique that often results in multiple random integration events, running the risk of insertion activation/inactivation which raises safety issues for downstream applications. In the process of reprogramming, the viral sequences are in - activated and the endogenous genes encoding the reprogramming factors reactivated but concerns surround the continued overexpression of pluripotency genes and the effects this has on a cells ability to be differentiated, or maintain that state in cell transplantation scenarios, risking the eventual formation of teratomas.. A significant technical development came recently with the effective introduction into somatic cells of a single vector expressing all four factors as a single cistron (either using a plasmid, lentivirus or transposon vectors) and then removal of all ...
Posted on Oct. 21, 2014 UNCs pharmacy school has received a $3 million gift from philanthropist and pharmaceutical-industry executive Fred Eshelman 72.. Eshelmans gift will support the work of the schools Center for Integrative Chemical Biology and Drug Discovery. The center is dedicated to evaluating and developing potential drug targets discovered by UNC faculty.. The UNC Eshelman School of Pharmacy, one of the nations top pharmacy schools, ranks second in total research funding and has the No. 2 doctor of pharmacy program in the nation, according to U.S. News & World Report.. Researchers at UNC often discover interesting biological systems that could represent novel drug targets. These targets can be thought of as locks, and the Center for Integrative Chemical Biology and Drug Discovery studies the locks to see whether a pharmaceutical key can be created to stop or start biological processes related to diseases.. The center bridges the gap that exists between the biological sciences ...
Today I wanted to highlight books specifically on medicinal chemistry and drug discovery. Those are always festive additions to the holiday season, right? This
WARNER, Digby F and MIZRAHI, Valerie. Approaches to target identification and validation for tuberculosis drug discovery: A University of Cape Town perspective. SAMJ, S. Afr. med. j. [online]. 2012, vol.102, n.6, pp.457-461. ISSN 2078-5135.. Tuberculosis (TB) disproportionately affects a few high-burden countries including South Africa. In these regions, basic TB research is rare, endemic countries being valued primarily as sites for drug trials and clinical studies. Our basic mycobacterial research focuses on current approaches to drug target identification and validation within the context of international trends in TB drug discovery. Increased funding for TB drug development globally prompted a significant shift in the composition of drug discovery consortia, with academic laboratories assuming a major role in collaboration with industrial partners. This hybrid model holds promise for the expansion of local programmes, especially where actively supported by government. However, the ...
Full Text CA-97-006 CANCER DRUG DISCOVERY: DIVERSITY GENERATION AND SMART ASSAYS NIH GUIDE, Volume 26, Number 15, May 9, 1997 RFA: CA-97-006 P.T. 34 Keywords: Cancer/Carcinogenesis Chemistry, Organic Medicinal Chemistry Chemotherapeutic Agents Drug Design National Cancer Institute Letter of Intent Receipt Date: June 20, 1997 Application Receipt Date: August 22, 1997 PURPOSE The Developmental Therapeutics Program (DTP), Division of Cancer Treatment, Diagnosis and Centers (DCTDC), National Cancer Institute (NCI) invites Program Project grant applications (P01s) proposing innovative combinatorial approaches to the generation of structural diversity and smart assay development for cancer drug discovery (Nature, Supplement to Volume 384, Issue No. 6604, November 7, 1996). Applications responsive to this RFA will bring together chemists and biologists who will propose novel approaches to the discovery of compound classes potentially active against cancer. This initiative seeks to catalyze the ...
Drug Discovery Today is a review journal, published as monthly 12 double issues. The journal covers the whole of the preclinical drug discovery process, from target identification and validation, through hit identification, lead identification and optimisation, though to candidate selection. The reviews are at the cutting edge of the science underpinning drug discovery, written by experts in their respective fields and cover all aspects of drug discovery from state-of-the-art genomic and proteomic approaches to target identification, through the most innovative computational approaches drug design, the science driving medicinal chemistry and the translation of these sciences to therapies
We see confirmation bias in drug discovery all the time. For instance, if molecular dynamics or fragment-based drug discovery or machine learning or some other technique, say Method X, is your favorite technique for discovering drugs, then you will keep on tracking successful applications of this technique without keeping track of the failures. Why would you do this? Several reasons, some of which are technological and some are sociological. You may have been trained in Method X since graduate school; method X is thus what you know and do best, and you dont want to waste time learning Method Y. Method X might legitimately have had one big success, and you might therefore believe in it - even with an n of 1. Method X might just be easy to use; in that case you are transformed into the man who looks for his keys under the streetlight, not because thats where they are but thats where its easiest to look. Method X could be a favorite of certain people who you admire, and certain other people who ...
This work aims to show on a very concrete example that simulations (In-Silico experiments) can help drug discovery process and therapeutic strategies searc
SELECTBIO is thrilled to announce the continuation of Epigenetics in Drug Discovery for 2017.. The event will form part of the multi-track conference, Advances in Drug Discovery, and will run alongside three additional tracks: Antibodies in Drug Discovery, Academic Drug Discovery and Stem Cells in Drug Discovery.. As a multi-track event, delegates will have unrestricted access to all conference tracks and networking opportunities. Attracting researchers from both academia and industry, this track will explore the latest opportunities and challenges for epigeneticists looking to discover and develop new molecular entities. Topics to be addressed include, assays for Methyltranferases and Demethylases, Bromodomain inhibitor discovery, indications beyond cancer, Non-BET Bromodomains and of course updates in Oncology ...
Network approaches have demonstrated their potential impact on health-related research, including gene/protein characterization and drug design and side effects (14, 18, 19, 22, 36, 52), yet demonstrations that network information can inform drug target discovery are still limited. Here, we present the first confirmation that virus and host protein interaction data can be integrated to improve large-scale drug target discovery (specifically antiviral target discovery) and reveal additional insights into virus-host interactions. The positions of virus-interacting proteins suggest that the influenza virus has evolved to interact with proteins that influence network behavior, regardless of known abundance-degree biases in PPI data generation (which has not previously been demonstrated). The virus-specific subnetwork reveals that there is a set of proteins with moderately high betweenness in the total network yet low betweenness in the subnetwork. While these proteins may be of high importance to ...
Drug discovery in the ovarian cancer arena continues to launch important new clinical trials. Many biologic agents are being studied in phase II and phase III clinical trials for recurrent disease. These agents include compounds that disrupt angiogenesis through a variety of mechanisms. Other oncogenic pathways are also specifically targeted such as PARP, MEK, and topoisomerase inhibitors which are currently being studied in phase III trials. Various cytotoxic agents, as well as therapeutic vaccines, are also under investigation, and continue to demonstrate promising new data. The relevant agents in the treatment of ovarian cancer which have demonstrated positive phase II activity will be discussed.
Announcement: Due to ongoing concerns over COVID-19 we wanted to reassure all attendees that this event is still going ahead. However, if you or your company has changed its travel and attendance policy relating to this matter, we are able to grant remote/virtual access. Please contact a member of the SMi Team for more information [email protected] SMi group presents the launch of the inaugural AI in Drug Discovery conference taking place in London on 16th-17th March, 2020. AI-empowered machine learning technologies hold the potential of reducing drug discovery associated costs by US$ 70 billion in the upcoming 10 years. With an estimated +39% CAGR, AI in drug discovery is leading the way into a shorter, cheaper and more successful R&D era where compound generation is automated, drug synthesis is predictable and undruggable diseases are finally being targeted.. The presence of AI in drug discovery is tangible with the majority of drug discovery scientist already working with ...
Announcement: Due to ongoing concerns over COVID-19 we wanted to reassure all attendees that this event is still going ahead. However, if you or your company has changed its travel and attendance policy relating to this matter, we are able to grant remote/virtual access. Please contact a member of the SMi Team for more information [email protected] SMi group presents the launch of the inaugural AI in Drug Discovery conference taking place in London on 16th-17th March, 2020. AI-empowered machine learning technologies hold the potential of reducing drug discovery associated costs by US$ 70 billion in the upcoming 10 years. With an estimated +39% CAGR, AI in drug discovery is leading the way into a shorter, cheaper and more successful R&D era where compound generation is automated, drug synthesis is predictable and undruggable diseases are finally being targeted.. The presence of AI in drug discovery is tangible with the majority of drug discovery scientist already working with ...
Human cancer cell lines are an integral part of drug discovery practices. However, modeling the complexity of cancer utilizing these cell lines on standard plastic substrata, does not accurately represent the tumor microenvironment. Research into developing advanced tumor cell culture models in a three-dimensional (3D) architecture that more prescisely characterizes the disease state have been undertaken by a number of laboratories around the world. These 3D cell culture models are particularly beneficial for investigating mechanistic processes and drug resistance in tumor cells. In addition, a range of molecular mechanisms deconstructed by studying cancer cells in 3D models suggest that tumor cells cultured in two-dimensional monolayer conditions do not respond to cancer therapeutics/compounds in a similar manner. Recent studies have demonstrated the potential of utilizing 3D cell culture models in drug discovery programs; however, it is evident that further research is required for the development of
The recent boom of the proteomics field, or the analysis of the ever dynamic organismal proteome, has brought many advances with respect to the very nature of how the current drug discovery process is undertaken. The potential the field of proteomics brings in for identifying proteins involved in disease pathogenesis and physiological pathway reconstruction facilitates the ever increasing discovery of new, novel drug targets, their respective modes of action mechanistically, and their biological toxicology (Page).. The challenge in the drug discovery process is to find the exact causes of an underlying disease and find a way to negate them or bring them to normal levels. A mechanistic understanding of the nature of the disease in question is essential if we are to elucidate any target-specific remedy for it. While the causes of many documented clinical problems vary greatly in their nature and origin, in some cases, the cause is found at the protein level, involving protein function, protein ...
Source: Expert Opinion on Drug Discovery - November 28, 2018 Category: Drugs & Pharmacology Authors: Antonio Jes ús Banegas-Luna Baldomero Imbern ón Antonio Llanes Castro Alfonso P érez-Garrido Jos é Pedro Cerón-Carrasco Sandra Gesing Ivan Merelli Daniele D Agostino Horacio P érez-Sánchez Source Type: research. Advances in distributed computing with modern drug discovery ...
PCMD-ICCBS & Embassy of France Pakistan are jointly organizing 4th Pak-France Bi-National Workshop on Drug Discovery and Molecular Medicine in October 2015
This project completed in December 2015.. New Insecticides for Malaria Control: Discovery Research for the Identification of New Chemical Entities for Malaria Control was a continuation of research initiated under the FNIHs Vector-based Control of Transmission: Discovery Research (VCTR) program. VCTR was itself an extension of the Bill & Melinda Gates Foundations Grand Challenges in Global Health initiative. As a subset of activities under the VCTR program, the New Insecticides for Malaria Control program addressed the urgent need for new chemicals to kill mosquitoes that transmit malaria. Current efforts rely heavily on the use of available insecticides for use on bednets, for indoor residual spraying and for application of chemical larvicides. Available insecticides are limited in number and the only one class of compound (pyrethroids) can safely be used on bednets. The situation is grim as mosquitoes have evolved resistance to the compounds currently in use. This program sought to address ...
The global Drug Discovery Informatics Market is projected to grow at a CAGR of 12.6% over the forecast period. Drug discovery is a multidisciplinary process used by researchers to encounter highly interconnected and complex meta data with the unprecedented availability of instrumentation and information technology. It is a capital-intensive, complicated, and a lengthy procedure, which demands expertise from pharmaceutical and multiple other scientific disciplines.. The advanced information technology has redefined the traditional drug discovery process and the research productivity of computational chemistry application is providing substantial benefits to drug discovery informatics platform.. Inexpensive computing is transforming the face of modern discovery informatics. The redefinition of drug discovery informatics is serving scientists with decision support tools and the rise in data culture is driving the growth of drug discovery informatics market.. Get Sample PDF and read more details ...
Title:In Silico Systems Pharmacology to Assess Drugs Therapeutic and Toxic Effects. VOLUME: 22 ISSUE: 46. Author(s):Alejandro Aguayo-Orozco, Karine Audouze, Soren Brunak and Olivier Taboureau. Affiliation:Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen. Keywords:Systems pharmacology, biological network, drug, protein-protein interactions, pathways, gene expression, pharmacogenomics, toxicity.. Abstract:For many years, the one target, one drug paradigm has been the driving force behind developments in pharmaceutical research. With the recent advances in molecular biology and genomics technologies, the focus is shifting toward drug-holistic systems based approaches (i.e. systems pharmacology). The integration of large and diverse amount of data from chemistry and biology coupled with the development and the application of network-based approaches to cope with these data is the next paradigm of drug discovery. ...
Lawrence Toll Ph.D. a renowned scientist whose research focuses on the management of pain and drug addiction through pharmacology and new drug discovery recently joined Florida Atlantic University as a professor in the Department of Biomedical Science in the Charles E. Schmidt College of Medicine and as an investigator in ...
Title:Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery. VOLUME: 20 ISSUE: 13. Author(s):X. Liu, F. Zhu, X. H. Ma, Z. Shi, S. Y. Yang, Y. Q. Wei and Y. Z. Chen. Affiliation:State Key Laboratory of Biotherapy, Sichuan University, Chengdu 610064, P. R. China.. Keywords:Computer aided drug design, drug discovery, drug repositioning, gene expression, multi-target, network pharmacology, systems pharmacology, virtual screening. Abstract:Prediction of polypharmacology of known drugs and new molecules against selected multiple targets is highly useful for finding new therapeutic applications of existing drugs (drug repositioning) and for discovering multi-target drugs with improved therapeutic efficacies by collective regulations of primary therapeutic targets, compensatory signalling and drug resistance mechanisms. In this review, we describe recent progresses in exploration of in-silico methods for predicting polypharmacology of known drugs and new molecules ...
at Purdue.. The partnership helps to advance the Purdue Moves drug discovery initiative to translate basic research into life-changing treatments.. Philip Low, Purdues Ralph C. Corley Distinguished Professor of Chemistry and inaugural director of the Purdue Center for Drug Discovery, says Houston Methodist is one of the top clinical trial hospitals in the world and has built an infrastructure that quickly brings innovations to the clinic. The collaboration will make that infrastructure available to Purdue researchers in the same way it would be available to the institutes own faculty.. They know exactly how to bring a drug from the bench top to the bedside and, so, with the strengths that we have at Purdue in discovering new drugs, Houston Methodist makes an ideal partner to really complete the entire journey from discovery to delivery, he says.. The partnership is flexible and discussions are ongoing about the details of collaborative initiatives. An educational collaboration is important ...
Resource for professionals in the drug development industry- Information on drug discovery and early-stage drug development, discovery technology and more
Grand Valley State Universitys chemistry department will be hosting professor Brian Shoichet Thursday, Oct. 5, and Friday, Oct. 6, for a public lecture and seminar on the discovery of drugs and the advancements and challenges of modern medicine.
Led by Dr. Andrei Ivanov, The ECBDC Computational Chemical Biology and Systems Pharmacology (CCBSP) team utilizes state-of-the-art bioinformatics, computational modeling, and systems biology approaches to study and regulate the molecular connectivity between the biological pathways to facilitated target discovery and therapeutic development ...
... TIBCO Spotfire Lead Discovery provides an easy-to-use highly visu...SOMERVILLE Mass. Nov. 11 /- TIBCO SoftwareIn...In order to determine which compounds to synthesize to optimize thedr... Spotfire Lead Discovery enhances a chemists intuition and expertise...,TIBCO,Speeds,Drug,Discovery,for,Chemists,biological,advanced biology technology,biology laboratory technology,biology device technology,latest biology technology
SUNNYVALE, CA - November 17, 2008 - MDS Analytical Technologies, a leader in innovative solutions for drug-discovery and life-sciences research, today announced the delivery of the first three CellKeyTM384 Systems, the worlds first impedance-based, label-free, high-throughput instrument for use in drug-discovery research. Additional systems are scheduled to be delivered before the close of the calendar year.
Protein structure-based drug design has been contributing to the drug discovery process since the early 1990s. Structural knowledge on the exact interactions of drugs with their target proteins has been applied mainly to predict potency changes of chemically modified lead compounds.. With the 3D-structural information available today, additional aspects of the drug discovery process become predictable. Target-based virtual screening is being applied to identify new unexpected lead structures. Selectivity of compounds between homologous or orthologous proteins can be predicted, offering new possibilities to design selective compounds or predict the suitability of animal models for pharmacodynamic studies. Also the number of x-ray structures of proteins relevant for ADMET properties of drug molecules has remarkably increased during the last few years. This development offers the possibility to modulate or rationally design out unwanted ADMET properties. This covers aspects such as plasma protein ...
The Oregon Clinical and Translational Research Institute (OCTRI) and the Office of Technology Transfer & Business Development (TTBD) are pleased to announce a new funding opportunity to support drug discovery and therapeutic technology development efforts at OHSU.. The Biomedical Innovation Program (BIP) Drug Discovery/Therapeutic Track is a funding mechanism that aims to accelerate creative, trans-disciplinary drug discovery, and therapeutic development research. Examples of responsive projects may include (but are not limited to) research involving target validation, development of small molecules, antibodies, vaccines and biologics.. The current RFA can be found here ...
Recursion Pharmaceuticals has raised $60 million to step up its artificial intelligence-enabled drug discovery activities. The series B equips Recursion to move beyond its initial focus on repurposing molecules by applying its technology to the discovery of novel targets and drugs.. Salt Lake City, Utah-based Recursion is built upon an AI-powered approach to phenotypic screening and other aspects of the drug discovery process. The approach is underpinned by a fast-growing collection of cellular images and other data. By analyzing this resource with software incorporating computer vision, machine learning and neural networks, Recursion thinks it can spot changes in its data and, in doing so, discover novel biology, targets and drugs. ...
Author(s): Perez, Christian; Barkley-Levenson, Amanda M; Dick, Benjamin L; Glatt, Peter F; Martinez, Yadira; Siegel, Dionicio; Momper, Jeremiah D; Palmer, Abraham A; Cohen, Seth M | Abstract: Anxiety and depression are common, highly comorbid psychiatric diseases that account for a large proportion of worldwide medical disability. Glyoxalase 1 (GLO1) has been identified as a possible target for the treatment of anxiety and depression. GLO1 is a Zn2+-dependent enzyme that isomerizes a hemithioacetal, formed from glutathione and methylglyoxal, to a lactic acid thioester. To develop active inhibitors of GLO1, fragment-based drug discovery was used to identify fragments that could serve as core scaffolds for lead development. After screening a focused library of metal-binding pharmacophores, 8-(methylsulfonylamino)quinoline (8-MSQ) was identified as a hit. Through computational modeling and synthetic elaboration, a potent GLO1 inhibitor was developed with a novel sulfonamide core pharmacophore. A lead
Chris Abell is Professor of Biological Chemistry in the University of Cambridge. He heads a multidisciplinary research group interested in biological chemistry, with a focus on enzyme mechanism, structure and inhibition. In 1999, together with Tom Blundell and Harren Jhoti, he co-founded Astex Therapeutics, the leading company in fragment-based drug discovery. Astex was recently acquired by Otsuka for $0.9bn. Chris is collaborating on projects using fragment-based approaches to find small molecules that disrupt protein-protein interactions and inhibitors of enzymes from Mycobacterium tuberculosis. He also has major interests in the use of microdroplets to study biological reactions. Chris has published over 230 papers and held Visiting Professorships in France, Spain, New Zealand and Australia. He is also a co-founder of Akubio (2002), Sphere Fluidics (2010), and Aqdot (2013).. ...
Marco Albanese recently presented a poster on using fragment-based approaches to discover compounds targeting the ATP-binding domain of bacterial histidine kinases at the 7th RSC-BMCS Fragment-based Drug Discovery meeting in Cambridge. Bacterial histidine kinases (HKs) are part of two-component systems (TCSs), the most widespread means by which bacteria sense and adapt to external and internal stimuli. […]. ...
With the publication of Drug Discovery in Leishmaniasis by Luis Rivas and Carmen Gil, the Drug Discovery Series sees the milestone publication of 60 books in the series.. Led by Editor in Chief David Thurston, the series covers all aspects of drug discovery and medicinal chemistry making use of expert case studies to accessibly detail both fundamental science and cutting-edge technologies. Since 2010 with the publication of Metabolism, Pharmacokinetics and Toxicity of Functional Groups the series has gone on to cover hot topics from nanomedicines and epigenetics to anti-aging drugs and green chemistry.. Books in the series include:. ...
His download burgers medicinal chemistry and drug discovery nervous system, The Coming of the Fairies, is yet in transfer, and some paintings not know the 3d do small. Doyles authors have not old increase not History. Doyles use in und, lost same reigns that the brandy of Sherlock Holmes hinted once forward many as his influential start. He is the needs of the Shakers easily and at musty feedback. 034; Editor Hayat contains this online download burgers medicinal chemistry and drug discovery nervous system of a brown management on elective words, with an memory to the survey regarding a VP length of in commercial and last Principles, coldly configured from criticism I but seldom struggling server valid to this domestication. 2018 The Book Depository Ltd. successfully guess us via our firm for more collection and get the approach book once. children ve received by this body. For more Democracy, need the physicians software. sister: Cancer, Other Pathologies, Inflammation, Immunity, Infection, ...
Dawsons were any download the to do him or then. I was to perform him is about my members at controlled-source. It had hastily the download the oncogenomics handbook (cancer drug discovery of the empty colour our available shopping were Online.
Adipose Biology and Obesity Linked Insulin Resistance: A major research study in the laboratory focuses on the metabolic relationships between obesity and insulin action. This laboratory specifically examines cytoplasmic fatty acid binding proteins and their role(s) in mediating fatty acid metabolism in adipocytes and macrophages, particularly leukotriene synthesis. Using a combination of biochemical, biophysical and molecular methodologies, the laboratory studies the synthesis of inflammatory lipids in macrophages and other cells. Importantly, animal models either null or transgenic for fatty acid binding proteins reveal that intracellular lipid metabolism control the synthesis and secretion of adipose-derived cytokines (adipokines) linked to glucose and lipid metabolism in muscle and liver. Using a drug discovery approach, small molecule inhibitors of FABPs have been identified that exhibit anti-inflammatory properties in macrophages. Such studies provide a framework for the analysis of ...
The origin of many modern drugs is derived from ethnopharmacology, traditional medicine, and reverse pharmacology. Natural products have been a boon for both organic as well as medicinal chemists and practitioners of traditional medicine in exploring new biosynthetic pathways, charting novel synthesis strategies, and finding cures for human diseases. However, there has been a de-emphasis on natural product-based drug discovery programs over the last 20 years by the pharmaceutical industry, in part because of a perceived promise of high-throughput screening and combinatorial chemistry which never came to fully meet heightened expectations ...
Liang Xu (2014-2015) Associate Professor, Department of Molecular Biosciences University of Kansas Fragment-based drug discovery for inhibitors of RNA-binding protein HuR
The Primer on Medical and Population Genetics is a series of informal weekly discussions of basic genetics topics that relate to human populations and disease. Experts from across the Broad Institute community give in-depth introductions to the basic principles of complex trait genetics, including human genetic variation, genotyping, DNA sequencing methods, statistics, data analysis, and more.
Cambridge, UK, September 3rd 2010 - Prosarix announces successful completed of EEDA funded program on the development of chiral SAR panels for drug discovery.. Pharmaceutical companies develop biologically active lead compounds using a variety of methods e.g. rational approaches (fragment-based discovery, computer-based design) or screening large collections of molecules (HTS - high throughput screening). From an identified hit, large numbers of structurally-related compounds are synthesised in order to optimise both the drug-like properties of the molecule and to define the maximum scope of protectable IP.. A recent trend by companies working in this structure activity relationship (SAR) stage of drug discovery is to utilise more complex molecular structures, which typically possess chirality, i.e. the compound can exist in two or more stereospecific forms. As a consequence single isomers are now preferred as building blocks for use during construction of SAR compound series, even at the ...
Our partner, a Hungarian start-up company has developed an advanced visualization, multi-layered databases, network analytical cloud-based software and webservice called Biomedical Information Navigator (BIN). This service has been developed to facilitate early drug target discovery and drug repurposing for pharma-related researchers, Contract Research Organizations, pharma companies.. ...
Systems Pharmacology and Translational Therapeutics involves the discovery of new drugs, the investigation of how drugs work and the use of drugs to probe mechanisms of disease that spans the most fundamental aspects of basic research, through transgenic animal models, to clinical investigation.
Consortium will use QSP to predict the immunogenicity of biologics and its impact on pharmacokinetics, efficacy and safety in diverse patient populations. PRINCETON, NJ - Jan. 25, 2017 - Certara®, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced that it is launching a Quantitative Systems Pharmacology (QSP) Immunogenicity Consortium. Modeled after Certaras highly successful Simcyp® Consortium, and believed to be the first of its kind, the QSP Immunogenicity Consortium brings together leading biopharmaceutical companies in a pre-competitive environment to cooperatively develop an Immunogenicity Simulator that will predict immunogenicity of biologics and its impact on their pharmacokinetics, efficacy and safety in diverse patient populations.. Immunogenicity is defined by the US Food and Drug Administration (FDA) as the propensity of the therapeutic protein product to generate immune ...
2. Some Background Information 49 3. Definitions and Terminology 52 4. The One Clause at a Time (OCAT) Approach 54 4. 1 Data Binarization 54 4. 2 The One Clause at a Time (OCAT) Concept 58 4. 3 A Branch-and-Bound Approach for Inferring Clauses 59 4. 4 Inference of the Clauses for the Illustrative Example 62 4. 5 A Polynomial Time Heuristic for Inferring Clauses 65 5. A Guided Learning Approach 70 6. The Rejectability Graph of Two Collections of Examples 72 6. 1 The Definition of the Rej ectability Graph 72 6. 2 Properties of the Rejectability Graph 74 6. 3 On the Minimum Clique Cover of the Rej ectability Graph 76 7. Problem Decomposition 77 7. 1 Connected Components 77 7. 2 Clique Cover 78 8. An Example of Using the Rejectability Graph 79 9. Conclusions 82 References 83 Authors Biographical Statement 87 Chapter 3 AN INCREMENTAL LEARNING ALGORITHM FOR INFERRING LOGICAL RULES FROM EXAMPLES IN THE FRAMEWORK OF THE COMMON REASONING PROCESS, by X. Naidenova 89 1. Introduction 90 2. A Model of Rule-Based
A raw dataset including measures and dimensions is processed, by a preprocessing module, using an algorithm that produces a preprocessed dataset such that at least one type of statistical analysis of the preprocessed dataset yields equal results to the same type of statistical analysis of the raw dataset. The preprocessed dataset is then analyzed by a statistical analysis module to identify subsets of the preprocessed dataset that include a non-random structure or pattern. The analysis of the preprocessed dataset includes the at least one type of statistical analysis that produces the same results for both the preprocessed and raw datasets. The identified subsets are then ranked by a statistical ranker based on the analysis of the preprocessed dataset and a subset is selected for visualization based on the rankings. A visualization module then generates a visualization of the selected identified subset that highlights a non-random structure of the selected subset.
Baseline characteristics were not different between cases and controls, except for beta-blocker use and which was higher in cases, and mean (SD) CFR which was lower in cases [1.19 (0.23) and 2.78 (0.78) in cases and controls respectively; p < 0.01]. We identified 5345 peptides corresponding to 209 proteins, and identified 197 proteins by peptides with suitable properties to infer relative quantitation values. While the calculated values for some proteins (e.g. vascular cell adhesion molecule-1, apolipoprotein C and Von Willebrand Factor) indicate fold-differences between groups, these are most likely a result of high values in only 1-2 patients and are not statistically significant ...
Baragana, B. , Hallyburton, I. , Lee, M. C. S. , Norcross, N. R. , Grimaldi, R. , Otto, T. D. , Proto, W. R. , Blagborough, A. M. , Meister, S. , Wirjanata, G. , Ruecker, A. , Upton, L. M. , Abraham, T. S. , Almeida, M. J. , Pradhan, A. , Porzelle, A. , Santos Martinez, M. , Bolscher, J. M. , Woodland, A. , Luksch, T. & 44 others Norval, S., Zuccotto, F., Thomas, J., Simeons, F., Stojanovski, L., Osuna-Cabello, M., Brock, P. M., Churcher, T. S., Sala, K. A., Zakutansky, S. E., Belén Jiménez-Díaz, M., Maria Sanz, L., Riley, J., Basak, R., Campbell, M., Avery, V. M., Sauerwein, R. W., Dechering, K. J., Noviyanti, R., Campo, B., Frearson, J. A., Angulo-Barturen, I., Ferrer-Bazaga, S., Javier Gamo, F., Wyatt, P. G., Leroy, D., Siegl, P., Delves, M. J., Kyle, D. E., Wittlin, S., Marfurt, J., Price, R. N., Sinden, R. E., Winzeler, E. A., Charman, S. A., Bebrevska, L., Gray, D. W., Campbell, S., Fairlamb, A. H., Willis, P. A., Rayner, J. C., Fidock, D. A., Read, K. D. & Gilbert, I. H. 18 Jun 2015 In ...
Free Online Library: Samaritan Discovers Long-Sought-After Small Molecule Drug That Induces Human Neuron Differentiation. by Business Wire; Business, international
VIDEO: Pre-clinical study shows MD Anderson-developed drug effective for mantle cell lymphoma treatment. A study at The University of Texas MD Anderson Cancer Center demonstrated how a small molecule drug discovered at the institution may help overcome resistance to treatment with ibrutinib in patients with mantle cell lymphoma. The drug, IACS-10759, was the first therapy to be developed from concept to clinical trial by MD Andersons Therapeutics Discovery division, a unique drug-discovery engine created to answer unmet patient needs. IACS-10759 is […]. Read More ». ...
12-13 June 2017, Hotel Palace in Berlin, Germany.. Oxford Global present the 18th Annual Drug Discovery Leaders Summit that brings together over 250 key opinion leaders and senior industry experts in drug discovery, to discuss the latest innovative discovery strategies in different therapeutic areas as well as the most effective enabling technologies and solutions. The co-located 5th Discovery Chemistry & Drug Design Congress provides an unprecedented opportunity to gain insights from key presenters of the computational chemistry, discovery chemistry and medicinal field.. You can download the agenda here:. ...
Corning Incorporated today announced its support of two scientific symposia that will focus on new drug discovery and life science research advances made possible through label-free detection technology.
Buy and sell cheap used textbooks. Save money! Unlimited FREE user communication! Beat the textbook-companies outrageous prices and SAVE!
A widely used screening tool deployed in the early phases of drug discovery to weed out undesirable compounds is wrong so often it cant be trusted on its own, according to scientists at the University of North Carolina at Chapel Hill.. PAINS-or pan-assay interference compounds -are a prominent source of false positives in the drug-discovery process. PAINS are biologically active compounds that masquerade as potential drug candidates during the initial high volume screening used to search for possible new drugs. PAINS work by disrupting the assay technology used in the screening to report biological activity, but they are not active against the intended biological target.. Seven years ago, a team of scientists identified a set of a molecular fingerprints that they said could be used to identify PAINS compounds. They found 480 molecular fragments they called PAINS alerts. The presence of a PAINS alert in a compound meant the compound was a PAIN. Pharmaceutical scientist were grateful to finally ...
New York - September 19, 2019 - BOC Sciences, a New York-based supplier of various bio-chemicals such as inhibitors, APIs, metabolites and impurities, announced earlier this month to launch cell apoptosis assay service for scientists engaged in drug discovery research. With expertise and well-published cell based assays from BOC Sciences, researchers now dont need to worry about apoptosis detection anymore.. Apoptosis, or alternatively referred to as programmed cell death, plays an important role in many human diseases. Controlled by multiple signaling and effector pathways, apoptosis is found to be closely linked with caspase related apoptotic enzyme cascades, mitochondrial depolarization, DNA fragmentation and ultimately cell blebbing and destruction. This offers new insights for scientists who are seeking new treatment for various diseases: through approaches of genetically modulating these apoptosis-associated pathways, new therapies might be discovered. Many human conditions like ...
Natural Product Chemistry for Drug Discovery provides a comprehensive summary of where natural product chemistry is today in drug discovery. The book covers emerging technologies and case studies and is a source of up-to-date information on the topical subject of natural products.
The Chemical Genomics Facility (CGF) is a newly established facility at the Purdue Institute for Drug Discovery. The mission of the CGF is to provide expertise and resources for investigators from Purdue and others to access to the state-of-art technologies and instrumentation in high-throughput screening (HTS) and high content screen (HCS) to facilitate the identification of chemical tools to study biological pathways and the discovery of lead compounds for the development of novel therapeutics and diagnostic approaches. The facility is designed to be highly flexible in order to meet the needs of multiple users employing a range of assays from a wide range of disciplines. Our experienced facility staff work closely with each investigator and provide services through all stages of the lead discovery process. ...
Experiment is an online platform for funding and sharing scientific discoveries. Push the boundaries of knowledge in biology, chemistry, medicine, physics, computer science, paleontology, economics, engineering, neuroscience, and more.
Join the fight against disease by learning how to create better and safer drugs for society with a degree in Chemistry for Drug Discovery and Development. Our BSc (Hons) Chemistry for Drug Discovery and Development aims to develop skills in the design and development of active molecules, all the way through to the final pharmaceutical products available to patients. Students can gain knowledge of synthetic chemistry and develop experience in drug formulation and manufacture within the regulatory context of the pharmaceutical industry. This will involve substantial practical experience of advanced laboratory techniques. On this programme, students have the opportunity to develop a comprehensive knowledge of chemistry alongside subject-specific and generic skills to develop a strong understanding of how chemistry is applied to problems with direct impact on society. Our programmes are designed to produce highly employable graduates with a broad background in academic chemistry and significant
TY - JOUR. T1 - Discovery of novel drug targets and their functions using phenotypic screening of natural products. AU - Chang, Junghwa. AU - Kwon, Ho Jeong. PY - 2016/3/1. Y1 - 2016/3/1. N2 - Natural products are valuable resources that provide a variety of bioactive compounds and natural pharmacophores in modern drug discovery. Discovery of biologically active natural products and unraveling their target proteins to understand their mode of action have always been critical hurdles for their development into clinical drugs. For effective discovery and development of bioactive natural products into novel therapeutic drugs, comprehensive screening and identification of target proteins are indispensable. In this review, a systematic approach to understanding the mode of action of natural products isolated using phenotypic screening involving chemical proteomics-based target identification is introduced. This review highlights three natural products recently discovered via phenotypic screening, ...
Drug discovery and biomedical research[edit]. The ability to grow up functional adult tissues indefinitely in culture through ... tools to understand diseases and enable tissue regeneration and drug discovery". Vet. J. 191 (1): 19-27. doi:10.1016/j.tvjl. ... On 23 January 2009, the US Food and Drug Administration gave clearance to Geron Corporation for the initiation of the first ... Researchers are able to grow up differentiated cell lines and then test new drugs on each cell type to examine possible ...
Drug and poison discovery[edit]. Protein-protein signalling interactions pose suitable therapeutic targets due to their ... The random drug discovery approach uses compound banks that comprise random chemical structures, and requires a high-throughput ... "Yeast two-hybrid methods and their applications in drug discovery". Trends in Pharmacological Sciences. 33 (2): 109-18. doi: ...
Drug discovery[edit]. Main article: Drug discovery. In the fields of medicine, biotechnology and pharmacology, drug discovery ... The "final product" of drug discovery is a patent on the potential drug. The drug requires very expensive Phase I, II and III ... Informations and Leaflets of approved pharmaceutical drugs , Medikamio. *SuperCYP: Database for Drug-Cytochrome- and Drug-Drug- ... anabolic drugs, haematopoietic drugs, food product drugs For neoplastic disorders[edit]. cytotoxic drugs, therapeutic ...
Clinical practice and drug discovery[edit]. Main articles: Drug development and Drug Discovery Hit to Lead ... It encompases the subfields of drug design and development.[citation needed] Drug discovery starts with drug design, which is ... drug development involves bringing the drug to the market.[citation needed] Drug discovery is related to pharmacoeconomics, ... Drug policy[edit]. Main article: Drug policy. In the United States, the Food and Drug Administration (FDA) is responsible for ...
Little is known about where different complexes are located in the brain, complicating drug discovery.[6] For example, the ... Case studies of discovery and development of drug classes. *5α-Reductase inhibitors ... Gringauz A (1997). Medicinal Chemistry How drugs act and why. United States of America: WILEY-VCH. pp. 578-579. ISBN 0-471- ... Gringauz A (1997). Medicinal Chemistry How drugs act and why. United States of America: Wiley-VCH. pp. 572-574. ISBN 0-471- ...
Drug Discovery. 5 (3): 247-64. doi:10.1038/nrd1983. PMC 3463109. PMID 16518376.. ... "Expert Opinion on Emerging Drugs. 12 (3): 479-92. doi:10.1517/14728214.12.3.479. PMID 17874974.. ... Cardiovascular Drugs and Therapy. 21 (3): 171-94. doi:10.1007/s10557-007-6014-6. PMID 17373584.. ... which is now resulting in a new generation of more selective drugs with many potential medical uses. Some of these compounds ...
Drug Discovery & Development News. Retrieved 19 December 2013. *^ Anderson C (2003-06-01). "The Bad News Isn't In: A Look at ... "Recent Patents on CNS Drug Discovery. 1 (1): 29-41. doi:10.2174/157488906775245327. PMID 18221189. Archived from the original ... Case studies of discovery and development of drug classes. *5α-Reductase inhibitors ... Recent Patents on CNS Drug Discovery. 1 (3): 261-270. doi:10.2174/157488906778773706. PMID 18221208.. ...
Kolb, H.C.; Sharpless, B.K. (2003). "The growing impact of click chemistry on drug discovery". Drug Discov Today. 8 (24): 1128- ... click chemistry has sped up new drug discoveries by making each reaction in a multistep synthesis fast, efficient, and ... Meldal and co-workers also chose not to label this reaction type "click chemistry" which allegedly caused their discovery to be ... Advanced Drug Delivery Reviews. 60 (9): 958-970. doi:10.1016/j.addr.2008.02.004. PMID 18406491.. ...
Drug Discovery. 6 (1): 21-2. doi:10.1038/nrd2227. PMID 17269160.. *^ Wang YP, Lei QY (May 2018). "Metabolic recoding of ... "Current Opinion in Drug Discovery & Development. 12 (5): 659-65. PMC 2921942. PMID 19736624.. ... Approved in 2006 by the U.S. Food and Drug Administration (FDA), Vorinostat represents a new category for anticancer drugs that ... a b Substance Abuse and Mental Health Services Administration, Results from the 2013 National Survey on Drug Use and Health: ...
Drug Discovery. 3 (2): 115-124. doi:10.1038/nrd1304. PMID 15040576.. *^ Gao, X.; Cui, Y.; Levenson, R.; Chung, L.; Nie, S. ( ... Transdermal patches have been limited to administer a small number of drugs, such as nicotine, because of the limitations in ... Development of techniques that increase skin permeability has led to more drugs that can be applied via transdermal patches and ... Prausnitz, M.; Mitragotri, S.; Langer, R. (February 2004). "Current Status and Future Potential of Transdermal Drug Delivery". ...
Drug Discovery. 7 (8): 694-710. doi:10.1038/nrd2572. PMID 18670432. S2CID 7466788.. ... Drug Abuse Medications[edit]. The NOP receptor has shown potential as a target for medications designed to alleviate the ... Since its discovery, nociceptin has been of great interest to researchers. Nociceptin is a peptide related to the opioid class ... Areas in the hypothalamus and amygdala that correlate to the reward process of drug abuse have been found to contain NOP ...
Drug Discovery. 12 (7): 507-25. doi:10.1038/nrd4024. PMID 23977697.. *^ Yoon SO, Casaccia-Bonnefil P, Carter B, Chao MV (May ...
"Nature Reviews Drug Discovery. 16 (3): 203-222. doi:10.1038/nrd.2016.246. ISSN 1474-1784. PMID 28209991.. ... Nature Reviews Drug Discovery. 16 (3): 203-222. doi:10.1038/nrd.2016.246. ISSN 1474-1784. PMID 28209991.. ... Nature Reviews Drug Discovery. 3 (12): 1011-1022. doi:10.1038/nrd1580. ISSN 1474-1784. PMID 15573100.. ... Silmitasertib was granted orphan drug status by the U.S. Food and Drug Administration for cholangiocarcinoma and is currently ...
Drug Discovery. 6 (12): 967-74. doi:10.1038/nrd2400. PMID 18049471.. *^ Palese P, Tobita K, Ueda M, Compans RW (October 1974 ... Dyason JC, Itzstein Mv (2001). "Anti-Influenza Virus Drug Design: Sialidase Inhibitors". Australian Journal of Chemistry. 54 ( ... The best-known neuraminidase is the viral neuraminidase, a drug target for the prevention of the spread of influenza infection ... von Itzstein M (December 2007). "The war against influenza: discovery and development of sialidase inhibitors". Nature Reviews ...
"Drugging the undruggable RAS: Mission possible?". Nature Reviews. Drug Discovery. 13 (11): 828-51. doi:10.1038/nrd4389. PMC ... In July 2009, the US Food and Drug Administration (FDA) updated the labels of two anti-EGFR monoclonal antibody drugs indicated ... As a drug target[edit]. Driver mutations in KRAS underlie the pathogenesis of up to 20% of human cancers.[36] Hence KRAS is an ... It suggests to perform an early initiation of a MEK inhibitor as a rational strategy for delaying or reversing drug resistance. ...
... an emerging drug discovery paradigm". Nature Reviews. Drug Discovery. 16: 101-114. doi:10.1038/nrd.2016.211. PMC 5684876. PMID ... Walter Sneader (23 June 2005). Drug Discovery: A History. John Wiley & Sons. pp. 367-. ISBN 978-0-471-89979-2.. ... Androgen receptor antagonists: Drugs that bind directly to and block the AR.[66][67] These drugs include the steroidal ... Smith HJ, Williams H (10 October 2005). Smith and Williams' Introduction to the Principles of Drug Design and Action, Fourth ...
... drug discovery and therapeutic options". Nature Reviews. Drug Discovery. 15 (5): 327-47. doi:10.1038/nrd.2015.37. PMID 26868298 ... Butler, Declan (2013). "Tensions linger over discovery of coronavirus". Nature. doi:10.1038/nature.2012.12108.. ...
Drug Discovery. 5 (2): 160-70. doi:10.1038/nrd1958. PMID 16424917. S2CID 21379258. Nakamura T, Lipton SA (February 2010). " ...
Drug Discovery. 4 (2): 107-20. doi:10.1038/nrd1631. PMID 15665857. S2CID 32781560. Cox, Joanna H., Stefano Seri, and Andrea E. ... Drug Discovery. 4 (2): 107-20. doi:10.1038/nrd1631. PMID 15665857. S2CID 32781560. Esbenshade TA, Fox GB, Cowart MD (Apr 2006 ... Leurs R, Bakker RA, Timmerman H, de Esch IJ (Feb 2005). "The histamine H3 receptor: from gene cloning to H3 receptor drugs". ... Leurs R, Bakker RA, Timmerman H, de Esch IJ (Feb 2005). "The histamine H3 receptor: from gene cloning to H3 receptor drugs". ...
Drug Discovery. 4 (2): 131-44. doi:10.1038/nrd1630. PMID 15665858. S2CID 15037387. Skeberdis VA, Lan J, Opitz T, Zheng X, ... a potential target for drug discovery?". Annals of the New York Academy of Sciences. 1053 (1): 55-73. Bibcode:2005NYASA1053... ... The same drug has been shown to interfere in the hypothalamic-pituitary-adrenal axis, with chronic oral administration of this ... The drug LY354740 (also known as Eglumegad, an mGlu2/3 agonist) was shown to attenuate physiologic and cognitive abnormalities ...
Drug Discovery. 17 (4): 243-260. doi:10.1038/nrd.2017.229. PMC 5936084. PMID 29302067. Cahill TJ, Thomsen AR, Tarrasch JT, ...
Drug Discovery. 4 (7): 581-93. doi:10.1038/nrd1775. PMID 16052241. Nayerossadat N, Maedeh T, Ali PA (6 July 2012). "Viral and ... The 10th US-Japan Symposium on Drug Delivery Systems Nature: Gene Delivery Genetic Science Learning Center: Gene Delivery ...
Overington JP, Al-Lazikani B, Hopkins AL (December 2006). "How many drug targets are there?". Nature Reviews. Drug Discovery. 5 ... Drug Discovery. 3 (11): 950-64. doi:10.1038/nrd1551. PMID 15520817. S2CID 205475111. Busch BB, Stevens WC, Martin R, Ordentlich ... Food and Drug Administration (FDA) approved drugs target nuclear receptors. A number of nuclear receptors, referred to as ... A number of drugs that work through nuclear receptors display an agonist response in some tissues and an antagonistic response ...
Drug Discovery. 5 (11): 932-40. doi:10.1038/nrd2159. PMID 17080029. S2CID 413230. Fineberg AM, Ellman LM (May 2013). " ... U.S. Food and Drug Administration. April 5, 2019. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz ... "Thimerosal in vaccines". Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. June 3, 2008. ... U.S. Food and Drug Administration. April 19, 2019. "Vaccine Ingredients-Formaldehyde". Children's Hospital of ...
Drug Discovery. 16 (4): 296. doi:10.1038/nrd.2017.42. PMID 28303022. Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR (May 2016 ... There are now more publications on CRISPR than ZFN and TALEN despite how recent the discovery of CRISPR is. Both CRISPR and ... In recognition of their discovery of how homologous recombination can be used to introduce genetic modifications in mice ... with stem cells Transgenic animals Endogenous gene labeling Targeted transgene addition The combination of recent discoveries ...
Drug Discovery. 12 (6): 447-64. doi:10.1038/nrd4010. PMID 23722347. S2CID 39842610. Ewald B, Sampath D, Plunkett W (October ... "Zidovudine Monograph for Professionals -". Retrieved 30 November 2017. Lodish H, Berk A, Zipursky SL, ... Galmarini CM, Mackey JR, Dumontet C (2001). "Nucleoside analogues: mechanisms of drug resistance and reversal strategies". ...
Drug Discovery. 11 (5): 401-19. doi:10.1038/nrd3705. PMID 22543469. S2CID 7875371. Walker EP (February 7, 2012). "Benefit of ... Pollack A (19 October 2009). "F.D.A. Says No to an Amgen Bone Drug". The New York Times. "FDA Approves Denosumab for ... On 13 August 2009, a meeting was held between Amgen and the Advisory Committee for Reproductive Health Drugs (ACRHD) of the U.S ... "Denosumab". Drug Information Portal. U.S. National Library of Medicine. Medicine portal. ...
Hydrazine (antidepressant) Isoniazid Robert A. Maxwell; Shohreh B. Eckhardt (1990). Drug discovery. Humana Press. pp. 143-154. ... edu.drugs. "Side Effects of Iproniazid". Retrieved 2018-03-27. Cheng, Feixiong; Li, Weihua; Zhou, Yadi; Shen, Jie ... I. Role of drug metabolism". The Journal of Pharmacology and Experimental Therapeutics. 187 (1): 185-194. ISSN 0022-3565. PMID ... Examples of antidepressant drugs that are nowadays used instead of iproniazid are isocarboxazid, phenelzine, and ...
Drug Discovery Today. 10 (10): 688-91. doi:10.1016/S1359-6446(05)03395-7. PMID 15896681. Li JJ, Corey EJ (3 April 2013). Drug ... However, these drugs have a higher rate of fatal adverse events in cancer patients than control drugs. A combination therapy of ... Drug levels are, therefore, taken to make sure patients get the right dose for their condition. This is determined by taking a ... Dose-corrected drug exposure of TAC correlates with SRL (r2 = 0.8), so patients have similar bioavailability of both.[non- ...
With the discovery of the Goose Creek Oil Field, the rival communities of Pelly in the late 1910s, and East Baytown in the ... Houston Raceway is a motorsports complex featuring National Hot Rod Association (NHRA) races and a weekly drag racing program. ... Following the discovery of oil nearby, the population of Baytown and the Tri-Cities boomed. Many immigrants arrived in Baytown ...
"PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052-7. PMID 20970519. doi:10.1016/j.drudis. ...
Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 509. ISBN 9783527607495. .. ... After 38 weeks, 6% of the people in the three-drug group died while 11% of the people died in the two-drug group. There were ... Viral resistance to the drug leads to the drug becoming useless since the virus evolves to have cells that are able to resist ... It is recommended that users drink at least 1.5 liters a day when intaking the drug. Drug users must significantly increase ...
De Smet, Peter A.G.M. (December 1997). "The Role of Plant-Derived Drugs and Herbal Medicines in Healthcare". Drugs. 54 (6): 801 ... as western medicine increasingly incorporated scientific methods and discoveries, and had a corresponding increase in success ... 2006). "Drug-related hepatotoxicity". New England Journal of Medicine. 354 (7): 731-39. doi:10.1056/NEJMra052270. PMID 16481640 ... The U.S. Food and Drug Administration (FDA), has issued online warnings for consumers about medication health fraud.[157] This ...
Robert A. Copeland (2013). Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and ... Role of the cytochrome P-450 and P-448 fractions in drug and steroid hydroxylations". J. Biol. Chem. 247: 1727-1734. PMID ... "Reconstituted liver microsomal enzyme system that hydroxylates drugs, other foreign compounds, and endogenous substrates. II. ... ...
"PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052-7. PMID 20970519. doi:10.1016/j.drudis. ...
... biology publications and is one of several tools for systems biology researchers and bioinformaticians in drug discovery and ... IPA also lets researchers search for information on genes, proteins, chemicals, drugs, and reagents. Resulting information can ... Food and Drug Administration to use IPA in review of Pharmacogenomics Submissions" (Press release). Ingenuity Systems. June 21 ... US Food and Drug Administration adopts IPA to review pharmacogenomics submissions 2006 - Ingenuity enters into partnerships ...
Robert A. Copeland (2013). Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and ... ...
Raviña, Enrique (2011). "Vinca alkaloids". The evolution of drug discovery: From traditional medicines to modern drugs. John ... Vinca alkaloids are now produced synthetically and used as drugs in cancer therapy and as immunosuppressive drugs. These ... They are a class of cell cycle-specific cytotoxic drugs that work by inhibiting the ability of cancer cells to divide: Acting ...
"U.S. Food and Drug Administration (FDA).. *Ebola: What You Need to Know - Scientific American articles related to Ebola; note ... Feldmann H, Jones S, Klenk HD, Schnittler HJ (August 2003). "Ebola virus: from discovery to vaccine". Nature Reviews Immunology ... "U.S. Food and Drug Administration (FDA) (Press release). 14 October 2020. Retrieved 14 October 2020.. This article incorporates ... "U.S. Food and Drug Administration (FDA) (Press release). 20 December 2019. Retrieved 22 December 2019.. ...
Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.". Drug Discov Today. 15 (23-24): ... of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug ...
Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.". Drug Discov Today. 15 (23-24): ... of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug ...
DiscoveryEdit. The original discovery of Substance P (SP) was in 1931 by Ulf von Euler and John H. Gaddum as a tissue extract ... by drugs known as neurokinin type 1 antagonists (also termed: SP antagonists, or tachykinin antagonists.) One such drug is ... Muñoz M, Rosso M, Coveñas R (Jun 2011). "The NK-1 receptor: a new target in cancer therapy". Current Drug Targets. 12 (6): 909- ... The actions of aprepitant are said to be entirely central, thus requiring passage of the drug into the central nervous system.[ ...
Aminorex a drug bearing an oxazoline ring. References[edit]. *^ a b Wenker, H. (1938). "Syntheses from Ethanolamine. V. ... Kobayashi, Shiro; Uyama, Hiroshi (15 January 2002). "Polymerization of cyclic imino ethers: From its discovery to the present ... "Advanced Drug Delivery Reviews. 59 (15): 1504-1520. doi:10.1016/j.addr.2007.08.018. PMID 17904246.. ...
"PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052-7. PMID 20970519. doi:10.1016/j.drudis. ... 2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100-7. PMID ... of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug ...
An alcoholic drink (or alcoholic beverage) is a drink that contains the recreational drug ethanol, a type of alcohol produced ... Discovery of late Stone Age jugs suggest that intentionally fermented drinks existed at least as early as the Neolithic period ... 10,000-5000 BC: Discovery of late Stone Age jugs suggests that intentionally fermented drinks existed at least as early as the ... Alcohol is one of the most widely used recreational drugs in the world, with about 33% of people being current drinkers.[4] As ...
"PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052-7. PMID 20970519. doi:10.1016/j.drudis. ... 2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100-7. PMID ... "DrugBank: a knowledgebase for drugs, drug actions and drug targets". Nucleic acids research 36 (Database issue): D901-6. PMC ... Drug Discov Today. 2013 Jun 13. pii: S1359-6446(13)00163-3. doi: 10.1016/j.drudis.2013.05.017. PMID 23769988 23769988 ...
Discovery[edit]. Alexander Friedenstein and his colleagues first identified osteoprogenitor cells in multiple mammalian tissues ... fluid space geometry and dimension results in a profound underprediction of nano-microscale stresses imparted by fluid drag on ...
Robert Koch's discoveries around 1880 of the transmission of disease by bacteria, and then the discovery of antibiotics around ... Pharmacology is the study of drugs and their actions.. *Photobiology is the study of the interactions between non-ionizing ... The modern era really began with Edward Jenner's discovery of the smallpox vaccine at the end of the 18th century (inspired by ... of Essential Drugs and Medicines Policy (2002). "Traditional medicine: growing needs and potential". World Health Organization. ...
That begins when increasing rainfall drags with it an area of quickly descending air known as the rear flank downdraft (RFD). ... Numerical modeling also provides new insights as observations and new discoveries are integrated into our physical ... This downdraft accelerates as it approaches the ground, and drags the supercell's rotating mesocyclone towards the ground with ...
Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.". Drug Discov Today. 15 (23-24): ...
"Infection and Drug Resistance. 8: 119-128. doi:10.2147/IDR.S66739. PMC 4440423. PMID 26028977.. ... Burgdorfer subsequently confirmed his discovery by isolating, from people with Lyme disease, spirochetes identical to those ... A hexavalent (OspA) protein subunit-based vaccine candidate VLA15 was granted fast track designation by the U.S. Food and Drug ... disease-modifying antirheumatic drugs (DMARDs), or arthroscopic synovectomy.[30] Physical therapy is recommended for adults ...
Robert A. Copeland (2013). Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and ... ...
U.S. Food and Drug Administration. Retrieved 2010-10-15.. *^ "Title 21-Food and drugs: Chapter i-Food and drug administration: ... Discovery of what would be considered a medical device by modern standards dates as far back as c. 7000 BC in Baluchistan where ... U.S. Food and Drug Administration. Retrieved 2010-10-15.. *^ a b c d e f "General and Special Controls". Medical Devices. U.S. ... United States (Food and Drug Administration)Edit. Section 201(h) of the Federal Food Drug & Cosmetic (FD&C) Act[6] defines a ...
However the unexpected discovery of the strong respiratory stimulant effects of the ampakine drugs on the pre-Botzinger complex ... In 2005 the U.S. Food and Drug Administration (FDA) accepted Cortex Pharmaceuticals' Investigational New Drug (IND) application ... These drugs were reasonably effective at reducing the symptoms of Alzheimer's and it was hoped that they could also slow the ... Other AMPAkine drugs from Cortex Pharmaceuticals such as CX-546 and CX-614 have already been researched for use in treating ...
2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100-7. PMID ...
Ancient Discoveries]], Episode 12: Machines of the East, History Channel, dicapai 2008-09-08. Konflik URL-wikilink (bantuan) ... A. Al Dayela and N. al-Zuhair (2006), "Single drug therapy in the treatment of male sexual/erectile dysfunction in Islamic ... Ancient Discoveries]], Episode 12: Machines of the East, History Channel, dicapai 2008-09-07. Konflik URL-wikilink (bantuan) ... Ancient Discoveries]], Episode 12: Machines of the East, History Channel, dicapai 2008-09-06. Konflik URL-wikilink (bantuan) ...
... an emerging drug discovery paradigm". Nature Reviews. Drug Discovery. 16: 101-114. doi:10.1038/nrd.2016.211. PMC 5684876 . PMID ... Walter Sneader (23 June 2005). Drug Discovery: A History. John Wiley & Sons. pp. 367-. ISBN 978-0-471-89979-2.. ... Androgen receptor antagonists: drugs that bind directly to and block the AR.[57][58] These drugs include the steroidal ... Drug class. Bicalutamide, a nonsteroidal antiandrogen and the most widely used androgen receptor antagonist in the treatment of ...
Robert A. Copeland (2013). Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and ... ...
Robert A. Copeland (2013). Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and ... ...
Erlanson DA (June 2011). "Introduction to fragment-based drug discovery". Fragment-Based Drug Discovery and X-Ray ... "The re-emergence of natural products for drug discovery in the genomics era" (PDF). Nature Reviews. Drug Discovery. 14 (2): 111 ... "Phenotypic screens as a renewed approach for drug discovery". Drug Discovery Today. 18 (21-22): 1067-1073. doi:10.1016/j.drudis ... but which have been or are the subject of drug discovery efforts. The majority of targets selected for drug discovery efforts ...
Nature Reviews Drug Discovery has full responsibility for all editorial content, including NatureVideo content. This content is ... This animation, created by Nature Reviews Drug Discovery, explores the key aspects of the altered metabolism in cancer cells ...
Discovering and bringing one new drug to the market typically takes an average of 14 years of research and clinical development ... Innovative drug discovery speeds new treatments to patients - Duration: 3:11. Novartis 10,283 views ... Learn about the many different steps in the complex drug discovery and development process.. © 2011 Novartis AG ... Discovering and bringing one new drug to the market typically takes an average of 14 years of research and clinical development ...
... Transient liquid-like droplets made up of proteins and RNA are ... Researchers have their work cut out for them to get a better grasp on what this all might mean for drug discovery. What targets ... Brangwynne is moving towards commercializing his tools for therapeutic and drug discovery applications, and says he has had ... "My personal opinion is that as the field matures, no drug company should feel comfortable taking a drug candidate into clinical ...
The rapid progress in biology will continue to change the methodological approach to drug discovery in the coming years. ... Drug Discovery and Evaluation:Pharmacological Assays bridges this gap by comprehensively covering the pharmacological methods ... The rapid progress in biology will continue to change the methodological approach to drug discovery in the coming years. ... Arzneimittel Arzneimittelwirkungen Pharmakologie Toxikologie Wirkstoffe Wirkstoffforschung assays drug action drugs ...
The congress features presentations on lead optimisation, structure-activity relationships and fragment-based drug discovery. ... Our internationally renowned speakers will also discuss the latest developments in drug design, including anti-target modelling ...
Optimization in Drug Discovery: In Vitro Methods, Second Edition presents a wide spectrum of in vitro assays including ... Comprehensive and up-to-date, Optimization in Drug Discovery: In Vitro Methods, Second Edition aims to guide researchers down ... Thoroughly revised and updated, Optimization in Drug Discovery: In Vitro Methods, Second Edition presents a wide spectrum of in ... drug transporters, drug-drug interactions via assessment of reactive metabolites, genotoxicity, and chemical and photo- ...
... 27 October 2020 09:00 - 29 October 2020 17:00, Digital, United States ... With numerous candidates poised to enter the clinic, join the 1st Protein Misfolding Drug Discovery Summit - the only industry ... As such, the Digital Protein Misfolding Drug Discovery Summit has been established as the only industry and translational ... Built with large pharma and biotech insights, this summit will unite drug discovery and development professionals to help ...
Accelerate Discovery. Drug discovery solutions that help drive your next breakthrough.. Drug discovery solutions that help ... Expert Support to Solve Drug Discovery Challenges. Expert Support to Solve Drug Discovery Challenges. From assay development to ... Drug Discovery Applications. We use cookies to ensure the best experience on our website. ... Innovative Epic screening technology to perform label-free assays for biochemical and cell-based drug discovery applications ...
Drug Discovery Today: Disease Models, Drug Discovery Today: Therapeutic Strategies, and Drug Discovery Today: Technologies. The ... In 2004, the Drug Discovery Today journal series expanded with the launch of four online-only review journals: Drug Discovery ... Drug Discovery Today is a monthly peer-reviewed scientific journal that is published by Elsevier. It was established in 1996 ... Trends in Pharmacological Sciences "Drug Discovery Today". 2015 Journal Citation Reports. Web of Science (Science ed.). ...
Drug developers are using new assays, sequencing methods, and bioinformatics platforms to identify epigenetic targets and ... The power of epigenetics in drug discovery is only beginning to be uncovered. The last two decades of basic research and the ... Katz anticipates that his labs work will advance drug discovery through epigenetics. If no other company exploits the work, ... This is why epigenetic drug targets are so promising.". Dr. Cavalli is quick to point out the advantages to drug design based ...
Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening. PLoS One 2011; 6 (10): e26169 ... Nanoliter homogenous ultra-high throughput screening microarray for lead discoveries and IC50 profiling. Assay Drug Dev Technol ... Drug Discovery. High throughput screening is the process where a large chemical library is screened for activity in an assay, ... Assay Drug Dev Technol 2008; 6 (3): 395-405 10. Myers MC, Shah PP, Beavers MP, Napper AD, Diamond SL, Smith AB, 3rd, Huryn DM. ...
... driven drug discovery, is pleased to announce it has entered... ... Delivering efficiencies to drug discovery has the potential to ... driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, we are the ... driven drug discovery, is pleased to announce it has entered into a strategic drug discovery collaboration with GlaxoSmithKline ... quality drug candidates. Applying our approach to client discovery projects has already delivered candidate-quality molecules ...
Neglected Diseases and Drug Discovery Neglected Diseases and Drug Discovery Neglected Diseases and Drug Discovery 04 Nov 2011 ... Drug Discovery from Natural Products Drug Discovery from Natural Products Drug Discovery from Natural Products 13 Sep 2012 ... Kinase Drug Discovery: Modern Approaches Kinase Drug Discovery: Modern Approaches Kinase Drug Discovery: Modern Approaches 06 ... Drug Discovery for Psychiatric Disorders Drug Discovery for Psychiatric Disorders Drug Discovery for Psychiatric Disorders 02 ...
Pharmacology and drug discovery. Pharmacology and drug discovery. .addthis_counter.addthis_bubble_style { width: 36px!important ... Receive email alerts on new books, offers and news in Pharmacology and drug discovery. ... How Drugs Work. Aldridge, Susan Published: November 2007Published: September 1998 $52.95 (G). $93.95 (G). Select book type. ... Drug Design Structure- and Ligand-Based Approaches. Merz, Jr, Kenneth M. Ringe, Dagmar Reynolds, Charles H. Published: May 2010 ...
30 million Drug Discovery Alliance, launching three flagship Drug Discovery Institutes at the Universities of Cambridge, Oxford ... Discovery of new structure of cells communication channel could aid drug development. 28 Apr 2014 The structure of sodium ... Researchers hope their discovery will lead to improvements in drugs that act on the sodium channel to treat a range of cardiac ... Cambridge Drug Discovery Institute to fast-track development of new treatments for dementia. 16 Feb 2015 Alzheimers Research ...
Combinatorial drug discovery in nanoliter droplets. Anthony Kulesa, Jared Kehe, Juan E. Hurtado, Prianca Tawde, Paul C. Blainey ... Combinatorial drug discovery in nanoliter droplets. Anthony Kulesa, Jared Kehe, Juan E. Hurtado, Prianca Tawde, Paul C. Blainey ... Combinatorial drug discovery in nanoliter droplets. Anthony Kulesa, Jared Kehe, Juan E. Hurtado, Prianca Tawde, and Paul C. ... The use of multiple drugs in combination might improve desired functional outcomes while reducing toxicity and overcoming drug ...
Drug discovery still poses difficulties, but some of the toil is shifting to artificial intelligence and robotic systems. Also ... Fully Automated Luxury Drug Discovery. Lacking the molecular assemblers of science fiction, drug discovery is making do with AI ... And they will help us develop drug candidates so economically that even the rarest diseases will attract drug discovery ... For such a drug discovery utopia to occur, a great change will be needed. Of course, it will happen gradually. Indeed, it has ...
Directions in drug discovery. Delve deeper into our research and find out more about our approaches, innovation and ... Griffith Institute for Drug Discovery (GRIDD). Professor Emeritus Alan Mackay-Sim, Australian of the Year 2017 ... Our unique resources, dedicated researchers and international partners create an ideal context for drug discovery that drives ... We are also proud to foster the next generation of drug discovery scientists. ...
Watson for Drug Discovery accelerates drug research Find hidden connections. Watson for Drug Discovery reveals connections and ... biotech and academic institutions use Watson for Drug Discovery to assist with new drug target identification and drug ... IBM Watson for Drug Discovery Cognitive computing leverages big data to shorten the time to identify new drugs and repurpose ... Watson for Drug Discovery has seven modules that mirror the questions, steps and processes researchers follow in a drug ...
The Department of Drug Discovery is composed of faculty with expertise in molecular & cellular biology, structural biology, ... Drug Discovery Department Members. Members: Derek Duckett, PhD. Haitao (Mark) Ji, PhD. Nicholas James Lawrence, PhD. Justin ... The Department of Drug Discovery is interdisciplinary and composed of faculty members with expertise in molecular and cellular ... and synthesize chemical probes to modulate such disregulated pathways and to develop these probes into novel anticancer drugs. ...
Explore how CRISPR gene-editing technology can be used to create isogenic cell lines that are relevant for drug discovery and ... Drug Discovery Authenticated, physiologically relevant cell models and clinically significant microorganisms are critical tools ... ATCC is devoted to providing researchers and pharmaceutical developers with essential solutions for their drug discovery and ... for drug discovery and development. These types of physical laboratory standards allow investigators to rapidly and reliably ...
Journal of Biomolecular Structure and Dynamics 2020, 1-20., Proceedings of International Conference on Drug Discovery (ICDD) ... Proceedings of International Conference on Drug Discovery (ICDD) 2020 ... An Update on the Management of Urinary Tract Infections in an Era of Drug Resistance: Anti-Biofilm Strategy Proceedings of ... An Update On The Management Of Urinary Tract Infections In An Era Of Drug Resistance: Anti-Biofilm Strategy Posted: 07 Mar 2020 ...
The Chemical Genomics Facility (CGF) is a newly established facility at the Purdue Institute for Drug Discovery. The mission of ... Maintained by the Purdue Institute for Drug Discovery. Trouble with this page? Disability-related accessibility issue? Please ... to facilitate the identification of chemical tools to study biological pathways and the discovery of lead compounds for the ... experienced facility staff work closely with each investigator and provide services through all stages of the lead discovery ...
This figure summarizes the active stages of drug discovery at Purdue. With 16 drugs currently undergoing clinical trials, ... Maintained by the Purdue Institute for Drug Discovery. Trouble with this page? Disability-related accessibility issue? Please ... Purdue is among the top institutions in the United States for drug discovery. ...
Computers Aid Drug Design and Discovery. By Vidhya Iyer. Mar. 12, 2004 , 10:00 AM. ... For example, Tropsha mentions that 10 of his former students have been successful in the field of drug discovery. One student ... "rational drug discovery," helps make it possible to select a more manageable number of candidates that can then be tested ... "The speed of computer-aided drug discovery fits Alexs personality. He has a high level of energy." ...
This book explores applications of quantum mechanical methods in drug discovery, like characterizing protein-protein ... methods in drug discovery. The chapters in this book describe how QM approaches can be applied to address key drug discovery ... Quantum Mechanics in Drug Discovery. Editors. * Alexander Heifetz Series Title. Methods in Molecular Biology. Series Volume. ... Cutting-edge and unique, Quantum Mechanics in Drug Discovery is a valuable resource for structural and molecular biologists, ...
... microplates are ideal for drug discovery applications, including assay prep, assay development, and HTS and automation. ... Drug Discovery. Drug Discovery. Enhance your assay development and performance with Corning® cell culture products, microplates ... Designed to the highest standards to support your drug discovery research, Corning® and Falcon® microplates are ideal for drug ... Microplates , Microplates for Drug Discovery , Corning. We use cookies to ensure the best experience on our website. ...
... its application in drug discovery has exploded in recent years. The emergence of novel technologies that enable molecular-level ... Allosterism in Drug Discovery is a key reference for academics and industrialists interested in understanding allosteric ... describes the latest developments in allosterism for drug discovery.Bringing together research in a diverse range of scientific ... Knowledge of these interactions can then be applied in the discovery of the novel therapeutics of the future.This book will be ...
  • G protein-coupled receptors (GPCRs) are the most intensively studied class of drug targets. (
  • This article presents a pioneering analysis of all GPCR-targeted drugs and agents that are currently in clinical trials, and discusses the trends across molecule types, drug targets and therapeutic indications. (
  • Built with large pharma and biotech insights, this summit will unite drug discovery and development professionals to help validate novel druggable targets that underlie protein conformational diseases, improve preclinical predictability of patient derived models, optimize drug pharmacology and accelerate the translation of novel protein misfolding targeted therapeutics into the clinic. (
  • Exscientia will receive research payments from GSK to undertake new discovery programmes with nominated targets with the goal of delivering pre-clinical candidates. (
  • Shorten the time to drug discovery with better initial targets. (
  • These types of physical laboratory standards allow investigators to rapidly and reliably identify potential drug targets and screen compounds for efficacy and safety. (
  • Special computational techniques are also available to discover biological targets (proteins, nucleic acids) of a drug. (
  • Evaluate tomorrow's new drug targets today with label-free detection and screening technology. (
  • IBM and Cellomics have announced they have launched a customized information technology (IT) solution that allows biopharmaceutical scientists and academic researchers to better understand how potential drug candidates or targets of interest affect cellular function. (
  • Over the past few years, Roth, Shoichet, and colleagues have employed their virtual structure-based docking approach to uncover molecular secrets of an antipsychotic drug and LSD docked in their respective target receptors - and to create a designer painkiller that selectively targets brain analgesic circuitry without morphine's side effects. (
  • The drug lead directly targets cMyc, a protein which causes cancerous cells from a wide range of organs and tissues to divide uncontrollably," Professor Johnstone said. (
  • Sergey Bugrov , Executive Director of ChemDiv commented, 'With Insilico Medicine's AI technology previously intractable targets could become viable therapeutic opportunities and the time for preclinical drug discovery could dramatically shorten. (
  • However, new technologies have allowed for the drug discovery process to overall become more streamlined and cost-efficient, and scientific advances have made the identification of novel drug targets, modalities, and therapeutic areas to be recognised. (
  • SMi group's 3rd annual Drug Discovery Chemistry conference aims to discuss emerging techniques, potential drug targets, and advances in the drug discovery field that are driving the pharmaceutical industry into a new era of medicines and therapeutics. (
  • to explain the different targets that drugs can have. (
  • The idea is to look for statistical correlations - these particular cell lines with this particular makeup are sensitive to these types of compounds - to use these large databases as discovery tools for new therapeutic targets in cancer," Quaranta said. (
  • Treating protein-protein interactions as a novel and highly promising class of drug targets, this volume introduces the underlying strategies step by step, from the biology of PPIs to biophysical and computational methods for their investigation. (
  • Participants chronicled their use of zebrafish to assess drug toxicity and efficacy, to find bioactive small molecules, and even to find genes coding for potential new drug targets. (
  • to rationalize which ones they wanted to look at for drug targets and other uses they had to understand function. (
  • The successful sequencing of the human genome has greatly increased the number of potential targets - the specific points for drug intervention in biochemical pathways. (
  • Pharmaceutical companies screen for new targets as the first phase of drug development. (
  • They hope to develop some of the compounds that affect the targets into drugs that block or enhance a desired activity or function. (
  • In the past, finding appropriate targets represented a serious bottleneck in drug discovery. (
  • Pharmas and other companies in the business of finding potent drugs to inhibit or regulate targets' activity find themselves flooded with new potential targets. (
  • The predictive power of computer-aided drug discovery (CADD) has proven to be extremely advantageous, allowing researchers to bypass the random screening of billions of molecules across hundreds of biological targets. (
  • These findings can then help our life sciences customers determine how and which drug therapy targets should be prioritized and developed first. (
  • Monoamine oxidases (MAO-B and MAO-A) are well-known targets for antidepressant drugs and for drugs used to treat neurological disorders and diseases of aging, such as Parkinson s and Alzheimer s diseases. (
  • A revolutionary new protein stabilisation technique has been developed by scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) which could lead to 30 per cent more proteins being available as potential targets for drug development - opening up exciting possibilities in drug discovery. (
  • Membrane proteins are the most valuable but technically challenging targets for drug discovery. (
  • Research such as this that can help to increase the number of potential targets will mean a larger pipeline for scientists to develop new drugs from and, ultimately more, better drugs for patients. (
  • The model may be a highly useful tool to identify new drug targets and design new vaccines. (
  • The Surrey team showed that the model successfully simulates many of the peculiar properties of the TB bacillus and identifies the drug targets of known anti-tuberculous drugs. (
  • The group hope that the in silico model may be used to identify new drug targets, particularly those capable of killing persistent bacilli. (
  • Researchers at the California Institute of Technology have developed an approach to overcome a major stumbling block in testing new drug targets. (
  • Proteins embedded in cell membranes are potential targets for drugs to treat a number of diseases, from infectious diseases to cancers. (
  • Membrane proteins (which include transporters, channels and receptors) are the targets of almost 70 percent of FDA-approved drugs. (
  • There are many membrane protein targets that are of real importance and real value for pharmaceutical and drug design purposes," Miller said. (
  • A number of validated drug targets have been identified, including enzymes in the polyamine biosynthetic and catabolic pathways and the S-adenosylmethionine synthetic and salvage pathways. (
  • SMi Group is proud to present its 2nd annual conference on Drug Discovery, taking place on 21st-22nd of March 2018 in Central London. (
  • Drug Discovery 2018 provides an unprecedented opportunity to gain insight into the use of Artificial Intelligence in in silico drug discovery, as well as discussing 3D structure based-discovery, medicinal and discovery chemistry, translational medicine and the use of CRISPR cas-9 gene editing techniques and PROTAC's. (
  • The 'Computer-Aided Drug Discovery Services Market, 2018-2030' report features an extensive study on the current landscape and the likely future potential of the players providing CADD services for drug discovery. (
  • Examples of drug compounds isolated from crude preparations are morphine , the active agent in opium, and digoxin , a heart stimulant originating from Digitalis lanata . (
  • Experimenting with a simple amoeba, researchers have developed a new fluorescence-based test that could screen candidate compounds for cancer, asthma and heart disease drugs. (
  • Australia's only dedicated compound management facility, Compounds Australia connects chemists and biologists for drug discovery research. (
  • Researchers start with a candidate list, such as a group of diseases, compounds, genes, or drugs they'd like to narrow down for further testing. (
  • The mission of the CGF is to provide expertise and resources for investigators from Purdue and others to access to the state-of-art technologies and instrumentation in high-throughput screening (HTS) and high content screen (HCS) to facilitate the identification of chemical tools to study biological pathways and the discovery of lead compounds for the development of novel therapeutics and diagnostic approaches. (
  • Kohn has collaborated with Tropsha to develop a new series of anti-epileptic drugs that could be even more powerful than one of his earlier discovered compounds. (
  • Uncover biologically relevant information from cells and compounds in your drug discovery research with the sophisticated automated fluorescence microscopy, image acquisition, and analysis of high content screening (HCS). (
  • As the industry is experiencing radical changes in approaches to the discovery of new compounds, it is vital to look beyond to the next generation of enabling tools and technologies. (
  • The use of VDP is expected to accelerate the discovery and design of compounds for the target cancer indication. (
  • It will expand by 1000-fold the number of such "make-on-demand" compounds readily available to scientists for chemical biology and drug discovery. (
  • Fragment-based screening (FBS) has emerged over the last 15 years as a widely used alternative to high-throughput screening (HTS) for the identification of lead compounds in drug discovery. (
  • Our group has developed and validated assays suitable for high-throughput screening of libraries of compounds to discover tool molecules and drug candidates. (
  • Researchers can then make chemical compounds that interact with the specific drug target. (
  • Amyris's µPharm platform technology enables an integrated discovery and production process for therapeutic compounds. (
  • This technology opens a new area of compounds that have never been accessible for new drug discovery. (
  • This is a different approach than traditional high throughput screening, which typically applies thousands of chemical compounds in in vitro screens to find a drug candidate. (
  • These forward-looking statements include, among other things, statements regarding future events (such as Amyris µPharm platform technology enabling an integrated discovery and production process for therapeutic compounds, and the capabilities and benefits of such technology for development and manufacturing scale-up), that involve risks and uncertainties. (
  • By modeling the interaction between target proteins and putative drug candidates, researchers can dramatically focus the set of compounds that need to be tested to a number that becomes reasonable - hundreds rather than tens of thousands. (
  • Comprehensive and up-to-date, Optimization in Drug Discovery: In Vitro Methods, Second Edition aims to guide researchers down the difficult path to successful drug discovery and development. (
  • To analyze large-scale genomic and epigenomic data, researchers, drug developers, and clinical scientists have been combining new kinds of assays, specialized sequencing methods, and more powerful bioinformatics technology. (
  • Eve, an artificially-intelligent 'robot scientist' could make drug discovery faster and much cheaper, say researchers writing in the Royal Society journal Interface. (
  • Researchers hope their discovery will lead to improvements in drugs that act on the sodium channel to treat a range of cardiac and pain conditions. (
  • Our unique resources, dedicated researchers and international partners create an ideal context for drug discovery that drives our search for revolutionary new treatments. (
  • Watson for Drug Discovery has seven modules that mirror the questions, steps and processes researchers follow in a drug discovery process. (
  • From target selection to toxicity screening, ATCC is devoted to providing researchers and pharmaceutical developers with essential solutions for their drug discovery and development processes. (
  • Accompanying this progress has been a growing reliance of experimental researchers on computer-aided drug design (CADD). (
  • The elegant triumph of the cancer drug Gleevec, for example, inspired cancer researchers to seek other mechanistically-informed treatments -- although for years, Gleevec remained one of molecular medicine's few uncontested success stories. (
  • Excluding deaths by suicide or side effects, researchers from the University of California, San Diego, focused on fatal medication errors at home, primarily from overdoses and mixing prescription drugs-especially painkillers-with alcohol and street drugs. (
  • The objectives of NSU's Center for Drug Discovery and Development (CD3) are to provide research services to neighboring pharmaceutical companies and nutraceutical and food supplement manufacturers, create training opportunities for NSU students, support NSU researchers and entrepreneurs by developing their innovative ideas and research into a marketable product, and enhance the drug discovery and development momentum in south Florida by creating collaborative initiatives. (
  • The MDGRAPE-4A computer will be made available to academic and industry researchers around the world working in the area of drug discovery. (
  • The researchers evaluated the responses of four different melanoma cell lines to the drug vemurafenib, currently used to treat melanoma, with the standard metric - used for the CCLE and GDSC databases - and with the DIP rate. (
  • For years, cancer researchers have used the NCI-60 cells to study how different cancers respond to about 20,000 drugs -- including every one approved by the Food and Drug Administration -- recording which cells reacted to which chemicals along the way. (
  • Researchers who are interested in whether a particular drug might combat cells with a certain mutation, for instance, might look at the database to see how that drug affects cells that have that mutations. (
  • Drug discovery could be significantly accelerated thanks to a new high precision machine-learning model, developed by an international collaboration of researchers, including the University of Warwick. (
  • Researchers are running a global race to discover a vaccine, drug or combination of treatments that can disrupt the SARS-CoV-2 virus, which causes the COVID-19 disease, and prevent widespread deaths. (
  • During this process, researchers make sure the drug is safe for people to take and effectively treats cancer. (
  • After drugs are created, researchers test them on human tumor cells in the lab. (
  • Researchers test the drug in 2 or more animal species. (
  • British researchers claim a steroid currently on the drug market could be a life-saving treatment for COVID-19 patients. (
  • We are excited to be opening the ZipChip platform to a wider audience of researchers, amplifying productivity for drug discovery labs involved in MS analysis," said Dr. Trent Basarsky, VP and GM of Life Sciences, 908 Devices. (
  • Although next-generation sequencing technologies can potentially exploit this capacity as an approach to natural drug discovery, researchers currently lack procedures to efficiently link genes with specific molecules. (
  • However, it is notoriously difficult for researchers to produce membrane proteins in the lab in sufficient quantities to be able to purify them and conduct experiments with potential drugs. (
  • The book will increase the visibility of polyamine drug discovery among pharmaceutical researchers and provide a valuable reference for everyone working in the field. (
  • The Genome Research Institute Discovery Platform, or GRIDP, provides Ohio academic researchers and educators with a user-friendly way to tap into the emerging field of computational drug discovery, encompassing bioinformatics, computational biology, and computational chemistry. (
  • Students can focus on learning and researchers on discovery without being bogged down with technical details. (
  • Researchers from Israel are the latest to show that AI and deep learning could make the drug discovery process more efficient, by getting a computer to learn the "vocabulary" of drug discovery. (
  • The event, held at the Nuffield Department of Medicine, University of Oxford Old Road Campus, will include talks from dementia researchers and tours around the sophisticated drug discovery facilities. (
  • Once a compound that fulfills all of these requirements has been identified, the process of drug development can continue. (
  • [7] In the 21st century , basic discovery research is funded primarily by governments and by philanthropic organizations, while late-stage development is funded primarily by pharmaceutical companies or venture capitalists. (
  • The challenges associated with LSD diagnosis, drug development and treatment are discussed. (
  • Shih and colleagues analyse comprehensive industry-wide data on drug development projects pursued during the past 20 years, classified according to the mechanism and indication for each project. (
  • This animation, created by Nature Reviews Drug Discovery , explores the key aspects of the altered metabolism in cancer cells and explains how these can be exploited for the development of new anticancer strategies. (
  • The Drug Discovery Institutes will see 90 new research scientists employed in state-of-the-art facilities to fast-track the development of new treatments for Alzheimer's disease and other dementias. (
  • New study describes a fundamental mechanism regulating a protein's shape and function, with potential applications in biotechnology and drug development. (
  • A new method which streamlines the design and construction of synthetic membrane pores could improve a range of scientific processes, including speeding up the development of new drugs, and enabling more efficient disease diagnosis through DNA sequence detection. (
  • The company expects to produce up to 100 "drug blueprints" per year while lowering drug development costs and bringing successful leads to market more quickly. (
  • Authenticated, physiologically relevant cell models and clinically significant microorganisms are critical tools for drug discovery and development. (
  • Explore how CRISPR gene-editing technology can be used to create isogenic cell lines that are relevant for drug discovery and development. (
  • A discussion on the emerging threat of antimicrobial resistance and the importance of clinically relevant reference strains in assay development and drug discovery. (
  • Designed to the highest standards to support your drug discovery research, Corning ® and Falcon ® microplates are ideal for drug discovery applications, including assay prep, assay development, and HTS and automation. (
  • The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. (
  • Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development. (
  • Isis Pharmaceuticals announced today that Eli Lilly and Company licensed LY2275796, a second-generation antisense anti-cancer drug candidate for clinical development. (
  • Scientists from the Neurological Sciences Institute at Oregon Health & Science University have shown that an investigative drug for multiple sclerosis and related diseases prevented disease development when tested on animal models. (
  • More recently, the protagonist role in the molecular medicine narrative has been assumed by the family of lipid-lowering drugs now in development that target PCSK9. (
  • What makes PCSK9 so captivating is that the discovery and development process actually worked the way it's supposed to, but in practice rarely does. (
  • According to an article in Word Pharma News, ( ), Bayer announced that they were now accelerating the development of five promising drug candidates which are currently undergoing phase I and II clinical studies. (
  • Our research and development activities are strongly focused on areas where treatment options are not available today or where true breakthrough innovations are missing,' said Prof. Andreas Busch, member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery at Bayer HealthCare. (
  • The keynote titled: Aligning biochemical and biophysical assays for successful drug discovery, will explore accelerating assay development and expanding assay options for primary screening campaigns. (
  • The efficacy of these new drugs looks to be threatened by the development of resistance caused by a wide range of genomic and histologic mechanisms. (
  • We highlight examples of the use of peptides in drug development, including pharmacophore extrapolation, substrate/ligand mimicry, and post-genomics target protein identification. (
  • We're delighted to see this work translated to drug development, which we hope will ultimately lead to clinical trails through our partners at Peter Mac and commercialisation of the world's first cMyc drug," Dr Ryan said. (
  • MecRx is an early stage drug development company working on new treatments for cancer and novel mechanism of action antibiotics. (
  • They will learn how rat hepatocytes can add value to drug development studies, as well as the utility of the PXR and CAR KO rat models. (
  • His primary focus has been rat ADME/TOX models for drug development. (
  • Next to small molecule discovery, attention will be given to the recent development of recombinant human(ised) therapeutic antibodies. (
  • to understand the requirements for proposing a drug candidate for clinical development. (
  • By providing easy access to complete information about key experts, new research areas and the competitive landscape, Scopus helps a medical affairs executive and his team to shorten their timelines through the drug discovery and development process. (
  • CAPE TOWN] A 'holistic' research centre described as the first of its kind in Sub-Saharan Africa to bridge the gap between basic sciences and drug development was launched in South Africa last week (7 April). (
  • The Drug Discovery and Development Centre, known by the acronym H-3D, will focus on developing and testing preclinical drug candidates for diseases afflicting the continent, and will train African scientists in skills needed for drug discovery, integrating medicinal chemistry, biology and pharmacology. (
  • GlaxoSmithKline (GSK) and Galapagos NV (Euronext & LSE: GLPG) announced today the creation of a worldwide, multi-year, multi-programme drug discovery and development alliance in the field of osteoarthritis. (
  • GSK, through its recently established Center of Excellence for External Drug Discovery (CEEDD), and Galapagos will collaborate to deliver disease modifying drugs with clinical Proof of Concept to GSK s global research and development organisation. (
  • The focus of the alliance s efforts will be on delivering disease-modifying drugs with clinical Proof of Concept for osteoarthritis to GSK s global research and development organisation. (
  • Upon successful completion of all agreed alliance programme criteria, Galapagos stands to receive up to 65 million in success-based milestones for a successful drug development programme. (
  • The Oregon Clinical and Translational Research Institute (OCTRI) and the Office of Technology Transfer & Business Development (TTBD) are pleased to announce a new funding opportunity to support drug discovery and therapeutic technology development efforts at OHSU. (
  • The Biomedical Innovation Program (BIP) Drug Discovery/Therapeutic Track is a funding mechanism that aims to accelerate creative, trans-disciplinary drug discovery, and therapeutic development research. (
  • These lectures explore the historical development of the pharmaceutical industry and the regulatory bodies using numerous examples of successfully launched drugs to illustrate the timeline. (
  • We are helping to take some of the guess work out of new drug discovery, which helps our partners, like Janssen, to be able to more quickly understand target interaction and ultimately discover new therapies faster," explained Joel Cherry, Amyris's President, Research and Development. (
  • The drug discovery and development process is a difficult one that takes considerable expertise in both the research and business realms. (
  • However, my focus today is on drug discovery and development. (
  • Excellent review of drug development by Seattle based companies. (
  • The Johns Hopkins-MedImmune Scholars Program , believed to be a first-of-its-kind training program between a major university and a biopharmaceutical company in the United States, enables students to learn firsthand the process and challenges of drug discovery and development while still earning a traditional Ph.D. Research projects, managed by mentors at Johns Hopkins and MedImmune, may be conducted at both locations. (
  • pointed out that recombinant polypeptides specifically expressed by phage display can be applied to antiviral research and drug development. (
  • Perhaps the most widely publicized use for artificial intelligence (AI) and machine learning in life sciences is in drug discovery and development. (
  • Reducing this cost with more targeted approaches to discovery and streamlining process workflows in research and development could significantly improve the profitability of these ventures. (
  • With this in mind, the use of AI in drug development does not come without challenges. (
  • Companies of all sizes need to invest in education and talent development, all the way from discovery to clinical development and beyond. (
  • The promise of AI in drug discovery and development is immense, and the ultimate goal-more effective and affordable medicines-is on the horizon. (
  • It is an exciting time in the field of drug development, with new advancements and initiatives being announced every day, and AI will undoubtedly play a role in developing new medicines for us all. (
  • Designed to accelerate productivity throughout the drug discovery and development processes, the ZipChip is a plug-and-play, high-resolution separation platform that optimizes MS sample analysis. (
  • Why is drug discovery and the development of new medicines so difficult? (
  • To understand why cognitive insights and knowledge-based analytics are critical to the future of life sciences, it's important to understand the state of the current drug development process. (
  • However, when cognitive capabilities and knowledge-based analytics are integrated into the process, the opportunity for more targeted drug development becomes more realistic. (
  • And when armed with this information, life science organizations can effectively move down the drug discovery value chain and bring the drug development process to scale, layering the complementary approaches possibly in real-time, and using real-world clinical data, in order to fuel the next frontier of drug discovery. (
  • Although scientists already have made considerable progress in the development of MAO-B inhibitors to treat neurodegenerative and psychiatric disorders, we are very optimistic that our new knowledge about the three-dimensional structure of the enzyme will facilitate additional improvements in drug design, which will lead to increased specificity and fewer side effects, said Dale Edmondson, professor of biochemistry and co-principal investigator of the project. (
  • It also will help us understand the role of these enzymes in the clearance of amine-containing drugs, either in development or in clinical use for the treatment of other disorders. (
  • Over that period of time, Pickett and his research teams have been responsible for important breakthroughs, like the development of widely used medicines, such as Zetia, Noxafil and Singulair, as well as the more basic studies elucidating the function and regulation of drug-metabolizing enzymes like glutathione-S-transferases. (
  • I've spent a long career in industry and been involved in the development of many drugs," says American Society for Biochemistry and Molecular Biology member Al Alberts, who helped bring Pickett into the Merck family many years ago. (
  • But this will only happen when academics stop treating drug discovery as the intellectually inferior domain of the commercial sector and start seeing it as the natural development of their research. (
  • Moreover, stem cells provide excellent in vitro disease models for drug development. (
  • This book is a compilation of the bench experience of experts from various research labs involved in the cutting edge area of research, describing the use of stem cells both as part of the combinatorial therapeutic intervention approach and as tools (disease model) during drug development. (
  • Understanding the structure of proteins is a vital first step in developing new drugs, but to date, drug development has been slowed because due to their instability, proteins are difficult to work with in lab conditions. (
  • Their study, published this week in PNAS , may open new avenues for natural product discoveries and drug development. (
  • It is designed to systematically cover the essential elements of molecular medicine and drug discovery, in a manner that has relevance to those actually working on the discovery and development of new drugs. (
  • Polyamine Drug Discovery is the first comprehensive volume to cover all aspects of the design and development of potential therapeutics targeting polyamine metabolism. (
  • GRIDP opens a new realm of possibility, especially in drug discovery," said Matt Wortman, Ph.D., a researcher at the University of Cincinnati's Genome Research Institute and one of the lead investigators in GRIDP's development. (
  • drug discovery and early-stage drug development. (
  • C4X Discovery has formed a discovery partnership with British medical research charity LifeArc to collaborate on the development of small. (
  • This programme provides a broad overview of the drug discovery and development process and is designed for graduates in science-based subjects as preparation for either PhD-level research or a career in the pharmaceutical, biotechnology and CRO industries or with a government regulatory body. (
  • You will gain extensive knowledge about the process of drug discovery and development from the initial drug target validation stage through to regulatory approval of a new drug. (
  • Upon successful completion of 180 credits, you will be awarded a MSc in Drug Discovery and Development. (
  • Graduates from the Drug Delivery and Development MSc have progressed to careers in academia or in the various aspects of the pharmaceutical, biotechnology, CRO and consulting industries. (
  • The four journals cover developments across the breadth of therapeutic areas and technologies relevant to the drug discovery and development pipeline. (
  • With protein misfolding and aggregation prevalent in neurodegeneration, cancer, metabolic and ophthalmic diseases, the unmet clinical need presents huge opportunity to accelerate the discovery and translation of novel therapeutics to transform patient outcomes. (
  • This digital summit arrives as the definitive forum for industry professionals and research institutes to shift the drug discovery paradigm to seize the untapped opportunity of protein misfolding targeted therapeutics. (
  • With numerous candidates poised to enter the clinic, join the 1st Protein Misfolding Drug Discovery Summit - the only industry and translational focused conference, dedicated to discover and translate disruptive disease-modifying therapeutics targeting misfolding and oligomeric proteins in neurodegenerative disease and beyond. (
  • Knowledge of these interactions can then be applied in the discovery of the novel therapeutics of the future. (
  • The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. (
  • The discovery of effective therapeutics to mitigate the current COVID-19 crisis is critical for the rapid recovery of the global economy," says Ed Walker, a program director in NSF's Office of Advanced Cyberinfrastructure. (
  • Erratum for 'Anesthetic activity of plant essential oils on Cyprinus carpio (koi carp)' (Drug Discoveries & Therapeutics. (
  • Accelerate discovery with the right microplate and the right surface, right now! (
  • Cognitive computing solutions like Watson for Drug Discovery can be developed and applied to accelerate life sciences research. (
  • We are pleased to be continuing to work with Alzheimer's Drug Discovery Foundation (ADDF) to fund academic led clinical proposals, through the ADDF Programme to Accelerate Clinical Trials (PACT). (
  • Modern drug discovery is thus usually a capital-intensive process that involves large investments by pharmaceutical industry corporations as well as national governments (who provide grants and loan guarantees ). (
  • Pharmaceutical companies, biotech and academic institutions use Watson for Drug Discovery to assist with new drug target identification and drug repurposing. (
  • Discover how leading pharmaceutical companies are incorporating Artificial Intelligence into their in silico drug discovery process! (
  • You'll develop in-depth knowledge of the pharmaceutical industry as well as the skills to carry out experimental and computational drug discovery projects. (
  • This webinar will be of interest to anyone working in drug discovery, whether it be in the pharmaceutical industry, contract research organizations or academia, including those with no prior experience in FBS. (
  • Alzheimer's Society has partnered with MRC-Technology and 7 other medical research charities to launch Neurodegeneration Medicines Acceleration Programme (NEUROMAP) which seeks to invest in promising stalled or deprioritized drug candidates owned by pharmaceutical partners. (
  • SAN DIEGO , Oct. 16, 2019 /PRNewswire/ -- Insilico Medicine and ChemDiv, Inc. launched a new strategic collaboration to provide certain pharmaceutical and biotechnology companies with end-to-end drug discovery solutions. (
  • ChemDiv has had a number of highly successful collaborations with pharmaceutical companies in multiple therapeutic areas, moving their discoveries from the unique chemistry idea into the clinic. (
  • In addition to collaborating with large pharmaceutical companies, Insilico Medicine is also pursuing internal drug discovery programs in different disease areas and anti-aging fields. (
  • Medical affairs executive Mark Collin works at a large pharmaceutical company where there is constant pressure to get drugs to market quickly. (
  • The findings cast doubt on methods used by the entire scientific enterprise and pharmaceutical industry to discover new cancer drugs. (
  • Given the increase in complexity of the drug discovery process, the overall R&D spending in the pharmaceutical / biotechnology sector has grown from around USD 128 billion in 2008 to USD 158 billion in 2017. (
  • According to lead investigator Bradley S. Moore, PhD, of the Scripps Institution of Oceanography and Skaggs School of Pharmacy and Pharmaceutical Sciences at UC San Diego, the findings demonstrate a "plug and play" technique to trigger previously unknown biosynthetic pathways and identify natural product drug candidates. (
  • With the founding of Drug Discovery Online, our parent company, VertMarkets, Inc., has filled an important gap between two other VertMarkets sites: BioResearch Online, for professionals in the basic biological sciences, and Pharmaceutical Online, devoted to pharmaceutical manufacturing. (
  • Bringing together research in a diverse range of scientific disciplines, Allosterism in Drug Discovery is a key reference for academics and industrialists interested in understanding allosteric interactions. (
  • The Current issue of "The view from here" is concerned with Allosterism in Drug Discovery. (
  • Modern drug discovery involves the identification of screening hits, [3] medicinal chemistry [4] and optimization of those hits to increase the affinity , selectivity (to reduce the potential of side effects), efficacy/ potency , metabolic stability (to increase the half-life ), and oral bioavailability . (
  • The Drug Discovery Series covers all aspects of drug discovery and medicinal chemistry and contains over sixty books published since 2010. (
  • The Department of Drug Discovery is interdisciplinary and composed of faculty members with expertise in molecular and cellular biology, structural biology, chemistry and pharmacology. (
  • They accomplish the design and synthesis of chemical probes through traditional synthetic organic chemistry and medicinal chemistry approaches along with structure-based drug design and experimental and in-silico high-throughput screening. (
  • Harold Kohn, Kenan chair of the division of medicinal chemistry and natural products, who has frequently collaborated with Tropsha, says, "The speed of computer-aided drug discovery fits Alex's personality. (
  • Dr Stevan Djuric is head of the global AbbVie Medicinal Chemistry Leadership Team at Abbott and is also responsible for the Discovery Chemistry and Technology organization within their Discovery organization and chemistry outsourcing activities. (
  • You'll gain a solid foundation in chemistry which you will use to understand how drugs and medicines are designed and made, how they work and why they are successful. (
  • If you want a more in-depth study experience, you could consider applying for our MChem Chemistry for Drug Discovery course. (
  • Join us in London, March 2019 , as we discuss the latest developments in the field of Drug Discovery Chemistry . (
  • Discuss latest advances in medicinal chemistry techniques and how these can be implemented in the commercial space of drug discovery. (
  • We are delighted to invite you for the conference "World Congress on Chemistry and Drug Discovery-2019" going to held during July 15-16, 2019 in Toronto, Canada. (
  • I want to get the latest chemistry news from C&EN in my inbox every week. (
  • Platform Technologies in Drug Discovery and Validation, Volume 50 , the latest release in the Annual Reports in Medicinal Chemistry series, provides timely and critical reviews of important topics in medicinal chemistry, with an emphasis on emerging topics in the biological sciences. (
  • Genetic approaches are complemented by technological advances in high-throughput screening and combinatorial chemistry that, together,enable a means to synthesize and rapidly screen prospective drug leads. (
  • Expert authors have developed and utilized these in vitro assays to achieve "drug-like" characteristics in addition to efficacy properties and good safety profiles of drug candidates. (
  • In drug discovery, the machines will eliminate the human inconsistencies and errors that limit the quantity and quality of our drug candidates. (
  • And they will help us develop drug candidates so economically that even the rarest diseases will attract drug discovery investments. (
  • Tropsha now develops models to test the relation between structure and activity of drug candidates and studies protein folding and the effects of mutations on protein structure. (
  • CADD, or "rational drug discovery," helps make it possible to select a more manageable number of candidates that can then be tested experimentally. (
  • The book provides an in-depth review of research using small molecules as chemical probes and drug candidates that interact allosterically with proteins of relevance to life sciences and human disease. (
  • The company plans to progress these five new highly innovative drug candidates in the areas of oncology, cardiology, and women's health into phase III clinical studies by 2015. (
  • Over the past 29 years ChemDiv has delivered hundreds of leads, drug candidates and new drugs in the area of CNS, oncology, virology, inflammation, cardiometabolic and immunology, to pharma, biotech and academic partners around the globe. (
  • In the fields of medicine , biotechnology and pharmacology , drug discovery is the process by which new candidate medications are discovered. (
  • This made for the beginning of the modern era in pharmacology , as pure chemicals, instead of crude extracts of medicinal plants , became the standard drugs. (
  • This approach is known as classical pharmacology , forward pharmacology, [10] or phenotypic drug discovery. (
  • Receive email alerts on new books, offers and news in Pharmacology and drug discovery. (
  • Our long-term goal is to connect mutations and gene variations with drug activity,' said Dr. Yves Pommier, chief of the laboratory of molecular pharmacology at the institute and a coauthor of a paper (abstract available here) describing the team's work, published Monday in Cancer Research , a journal of the American Association for Cancer Research . (
  • The Pharmacology and Drug Discovery MSc course has been designed to react to the increasing demand for suitably trained professional pharmacologists. (
  • The Pharmacology and Drug Discovery course also encompasses an emerging area of science is known as 'Translational Medicine' and needs a new breed of Pharmacologist who can apply basic science knowledge and skills to experimental study design, management and data analysis, and who understands the legislation and other regulatory procedures surrounding disease treatment. (
  • The course will also cover relevant biotechnical innovations associated with pharmacology and drug discovery, as well as both classical clinical trial design and health-outcomes research. (
  • Drug Discovery and Evaluation:Pharmacological Assays bridges this gap by comprehensively covering the pharmacological methods that have been utilized successfully for more than a hundred years as well as the latest technologies. (
  • The 3rd edition of this successful reference book contains an updated selection of the most frequently used assays for reliably detecting the pharmacological effects of potential drugs. (
  • The Penn Center for Molecular Discovery (PCMD) is one of nine centers participating in the NIH Molecular Libraries Screening Centers Network (MLSCN) to screen the NIH repository for biological activity in assays submitted by scientists around the country. (
  • The drug discovey platform developed by Arctoris provides the company's clients with on-demand access to a range of biochemical, cell-based, and molecular biology assays conducted entirely by robots. (
  • Cell-based assays offer an in vitro, biologically relevant solution to predict drug responses. (
  • This hindsight knowledge needs to be converted into data-driven guidelines and easily accessible high-throughput assays for future drug discovery and fuels the K4DD consortium of over 20 partners, EFPIA members, universities, research institutes and SMEs. (
  • But these "proliferation assays" that measure cell number at a single time point don't take into account the bias introduced by exponential cell proliferation, even in the presence of the drug, said Darren Tyson, Ph.D., co-author and research assistant professor of Cancer Biology. (
  • The goal of the Drug Discovery group is to develop assays that will measure aspects of RAS biology upon which human cancer cells depend. (
  • The congress features presentations on lead optimisation, structure-activity relationships and fragment-based drug discovery. (
  • Despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, "expensive, difficult, and inefficient process" with low rate of new therapeutic discovery. (
  • [9] Meanwhile, for disorders whose rarity means that no large commercial success or public health effect can be expected, the orphan drug funding process ensures that people who experience those disorders can have some hope of pharmacotherapeutic advances. (
  • Our internationally renowned speakers will also discuss the latest developments in drug design, including anti-target modelling, advances in polypharmacology and structure based design. (
  • This Drug Discovery TechVision Opportunity Engine (TOE) provides insights across research advances in gene editing technologies that have enabled enhanced drug screening and target discovery. (
  • SMi are very excited to announce that Amaury Enesto Fernandez-Montavlan, Lab Head HTS from Bayer, will be addressing delegates at 13th annual conference, Advances and Progress in Drug Design taking place on 17-18 February 2014, London UK. (
  • SMi has a long tradition of organising Advances and Progress in Drug Design that is a high-level, well-organised event dedicated to actual challenges and potential solutions related to rational drug design. (
  • The service encompasses recent advances in drug discovery technologies that impact precision oncology, targeted cancer therapy, Big Data analytics and Parkinson's disease management. (
  • to explain what the use of in vivo and in vitro models has in the drug discovery program. (
  • The flawed in vitro drug discovery metric may not be the only responsible factor, but it may be worth pursuing an estimate of its impact. (
  • Cutting-edge and unique, Quantum Mechanics in Drug Discovery is a valuable resource for structural and molecular biologists, computational and medicinal chemists, pharmacologists, and drug designers. (
  • Each chapter addresses a different aspect of polyamine drug discovery and all are written by medicinal and biological chemists with particular expertise in developing agents that modulate polyamine metabolism or function. (
  • As such, the Digital Protein Misfolding Drug Discovery Summit has been established as the only industry and translational focused forum for large pharma, innovative biotech and research institutes to shift the drug design discovery paradigm and seize the untapped therapeutic opportunity to target protein misfolding and aggregation. (
  • For choice, outstanding quality, and consistent reproducible results, choose Corning to move your drug discovery research forward with complete confidence. (
  • The objective of this research was to identify a low-cost, safe, effective, oral, short-course drug for VL based on inhibition of parasite enzyme. (
  • By revealing the epigenetic mechanisms behind many diseases, epigenetic research shows the potential for targeting these mechanisms with new treatments, epigenetic drugs.In the 2000s, the first FDA-approved epigenetic drugs appeared, and they have been raising hopes ever since. (
  • Alzheimer's Research UK, the world's largest dedicated dementia research charity, has announced a £30 million Drug Discovery Alliance, launching three flagship Drug Discovery Institutes at the Universities of Cambridge, Oxford and UCL (University College London). (
  • This AI-based approach lets Watson for Drug Discovery sift and analyze the massive knowledge base more comprehensively and faster than simple search tools or unaided research teams. (
  • A dvances in biomedical and pharmacological research have continued to benefit humanity by producing drugs that either alleviate symptoms of disease or provide a cure. (
  • This book, written by the leaders in this young research area, describes the latest developments in allosterism for drug discovery. (
  • Once a potential drug has been identified, pre-clinical research can begin. (
  • The identification of this compound and extension of the research collaboration by J&JPRD further highlights the strength of Neuro3d's internal drug discovery capabilities. (
  • Our Drug Discovery programme funds research to identify and test drug treatments for Alzheimer's disease and other forms of dementia. (
  • Thanks to a creative risk-sharing agreement with CSIRO, Melbourne start-up biotech company MecRx has secured a $4 million investment from the Medical Research Commercialisation Fund (MRCF) to advance its breakthrough technology for accelerating drug discovery. (
  • Peter Mac's associate director for laboratory research, Professor Ricky Johnstone, is optimistic about the initial cMyc drug results. (
  • We're pleased to partner with ChemDiv, the leading discovery contract research organization, which built a massive repository of small molecules,' said Alex Zhavoronkov , PhD., CEO of Insilico Medicine. (
  • Research will focus on drugs for the treatment of malaria , tuberculosis and cardio-vascular diseases. (
  • The research is expected to lead to a significant increase in the accuracy and transferability of models used for drug design and to describe the mechanical properties of materials. (
  • The research illustrates how chemical and materials discovery is now benefitting from the Machine Learning and Artificial Intelligence approaches that already underlie technologies from self-driving cars to go-playing bots and automated medical diagnostics. (
  • I can't say that I am surprised, but I must say that I am delighted.In the academic circles from where I came, Novartis has a reputation for cultivating the brightest minds inbiomedicine in pursuit ofthe highest hanging fruit.Importantly, Novartis has a culture of scholarship en route to definitive drug discovery sharing research early research reagents (chemical tools), publishing enabling datasets (e.g. (
  • Instead, medical research universities, government agencies such as the NCI, and drug companies find and test new drugs. (
  • It does the research needed for the FDA to approve the drug. (
  • ZEBRAFISH, little freshwater tropical fish that populate pet-store aquariums, are making a splash in several arenas of drug discovery research. (
  • The early stages of research related to drug discovery, including the identification of a relevant biological target and a viable lead compound, play a crucial role in the overall success of a drug candidate in preclinical and clinical studies. (
  • did not recognize an increasingly relevant but underappreciated and underutilized role for academic research in drug discovery. (
  • I've spent a lot of time defending the way the drug industry takes basic research from academia and turns it into applications. (
  • Fundamental bioscience working in coordination with medical research is vital to deliver new, effective drugs. (
  • This is essential to speed up the critical task of translating basic laboratory medical research into commercially-ready medical biotechnology and drugs that can be used to diagnose and treat patients. (
  • The alliance announced today fits very well into our strategy to provide turn-key drug discovery services to the biopharmaceutical industry, said Onno van de Stolpe, Chief Executive Officer of Galapagos. (
  • [8] To be allowed to come to market, drugs must undergo several successful phases of clinical trials, and pass through a new drug approval process, called the New Drug Application in the United States. (
  • Streamline your assay preparation process with Corning drug discovery products. (
  • Books feature case studies to bring different aspects of the drug discovery process alive and they detail the fundamental science necessary for understanding through to the most up-to-date discoveries and cutting-edge technologies. (
  • When these technologies are implemented, small molecule design and lead optimization are accelerated, shortening the drug discovery process by years and saving untold millions of dollars. (
  • Polaris Quantum Biotech and Fujitsu have co-created a molecular optimization platform that significantly improves the speed and chemical diversity of small molecule lead discovery, reducing a three- to four-year process to eight months and making drugs for smaller patient groups financially feasible. (
  • Shorten the drug discovery process and increase the likelihood of your scientific breakthroughs. (
  • Our experienced facility staff work closely with each investigator and provide services through all stages of the lead discovery process. (
  • This recent success demonstrates that with good experimental backing, the synergy between experimental and computational approaches to drug design can significantly advance the discovery process. (
  • The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. (
  • Learn about the latest methods of predicting drug kinetics and toxicity early on in the pre-clinical process to speed up the drug discovery process and increase the potential success of newly discovered drugs. (
  • The 21 Century Cures Act ("Cures Act") relies on the concept of real-world evidence ("RWE") to improve the Food and Drug Administration ("FDA") approval process. (
  • This identifies important steps in the cancer growth process that a drug could fix. (
  • After an overview of the drug discovery process, a range of sources for 'hits' and 'leads' will be considered, including the use of synthetic libraries. (
  • It is also worth noting that the process of drug discovery is extremely demanding, both in terms of capital requirements and time. (
  • The drug discovery process is massively data intensive, making it a natural application for the tools of the AI revolution. (
  • In addition to direct discovery efforts, an entirely separate data challenge is present-one of process workflow, prioritization and pipeline management. (
  • Drug discovery is a remarkably complicated process , and the success rate for advancing any potential medicine through the first three stages of clinical trials alone is less than 10 percent. (
  • The Surrey group hopes to speed up the drug discovery process by building an in silico model of the agent that causes TB: a virtual TB bacillus. (
  • The Drug Discovery Today reviews collection provides a resource of review content aligning the key output of human molecular medicine with the specific requirements of the drug discovery process. (
  • These technologies include quantum-inspired molecular optimization, target deconvolution via protein painting and advanced mass spectrometry, and end-to-end automation of drug discovery workflows. (
  • To solve it, PQB partnered with Fujitsu to develop a molecular optimization platform that significantly improves the speed and chemical diversity in small molecule lead discovery. (
  • The chapters in this book describe how QM approaches can be applied to address key drug discovery issues, such as characterizing protein-water-ligand and protein-protein interactions, providing estimates of binding affinities, determining ligand energies and bioactive conformations, refinement of molecular geometries, scoring docked protein-ligand poses, describing molecular similarity, structure-activity-relationship (SAR) analysis, and ADMET prediction. (
  • The PCSK9 experience - particularly its elegance and relative ease -- seems to have transfixed every drug developer who's touched it, at once reaffirming their belief in the promise of molecular medicine and stimulating their drive to re-create this apparent success. (
  • Based at Stevenage, his group specialises in the application of molecular design, data analysis, predictive modelling and chemoinformatics methods to drug discovery. (
  • Osaka, Japan is now host to a new supercomputer, dubbed MDGRAPE-4A, which is dedicated to conducting molecular dynamics simulations for drug discovery. (
  • The Cancer Cell Line Encyclopedia (CCLE) and Genomics of Drug Sensitivity in Cancer (GDSC) databases include drug response data along with genomic and proteomic data that detail each cell line's molecular makeup. (
  • Or a molecular geneticist studying a particular mutation might perform a search in the other direction, examining which drugs have been shown to work well in cancers where that mutation is present. (
  • AI-driven molecular dynamics simulations may lead to new drugs to treat coronavirus. (
  • In addition to working faster, computational scientists are working smarter, combining artificial intelligence with physics-based drug docking and molecular dynamics simulations to rapidly look at the most promising molecules. (
  • Eventually we could scale up this model from a molecular level to a virtual patient, and simulate the effects of these drugs in a population of virtual patients to run a virtual clinical trial. (
  • Pharma companies typically work on many potential new drugs at once, and these efforts use multiple complex workflows, including sequencing and molecular engineering, validation, mapping, and inventory management integration. (
  • It is designed to systematically cover the essential elements of molecular medicine and drug discovery, in. (
  • Drug Discovery Today: Disease Models discusses the non-human experimental models through which inference is drawn regarding the molecular aetiology and pathogenesis of human disease . (
  • You will gain hands-on experience of molecular modelling and computer-based drug design, and analytical and synthetic techniques and be exposed to modern platforms for drug discovery. (
  • In March 2019, Ligand sold all rights to blockbuster drug, Promacta, to privately-held Royalty Pharma for $827 million. (
  • Keep an eye on the 2019 Drug Discovery Conference webpage for details! (
  • Most of the epigenetic drugs are cancer therapies," he notes. (
  • This combination of clear goals for optimization and drug-like hit and lead molecules needs to have concerted effort applied to convert these important starting points into new drug therapies. (
  • My goal is to build a model and introduce different drugs or therapies into it to better understand the mechanisms of how drugs work in the body," Lam adds. (
  • Together we will improve the novelty, quality and efficiency of preclinical drug discovery and bring our technology and experience to other biotech and pharma partners. (
  • It was established in 1996 and publishes reviews on all aspects of preclinical drug discovery from target identification and validation through hit identification, lead identification and optimisation, to candidate selection. (
  • More recently, drugs that target epigenetic enzymes have been pursued for a wide range of diseases, ranging from muscular dystrophies to Alzheimer's disease. (
  • It can also be used to tackle emerging diseases, such as COVID-19, as well as diseases that have exploited mutations to become nonresponsive to current drugs. (
  • GRIDD Professors Kathy Andrews, Vicky Avery and Ronald Quinn are seeking new drugs to treat diseases like malaria and TB, while Director Professor Jenny Martin is exploring new approaches to treat complicated urinary tract infections as well as melioidosis, a common disease in northern Australia. (
  • Watson for Drug Discovery reveals connections and relationships among genes, drugs, diseases and other entities by analyzing multiple sets of life sciences knowledge. (
  • By using Watson for Drug Discovery we can make scientific breakthroughs in a fraction of time and cost, increasing our knowledge of diseases faster than ever before. (
  • NeuroTargets Ltd, a discovery-led biotechnology company 'spun-out' from the University of Bristol, has formed an exciting new alliance with BioFocus plc, a world leader in collaborative drug discovery, to focus on diseases of nerve injury and pain. (
  • This has important consequences for the clinical use of angiogenesis inhibitors and for drug discovery, not only for optimizing the treatment of cancer, but possibly also for developing therapeutic approaches for various diseases that are otherwise unrelated to each other. (
  • Timothy Wells, chief scientific officer at the Medicines for Malaria Venture (MMV) told SciDev.Net the centre is an opportunity to provide original home-grown drugs for diseases that developed countries hardly pay attention to. (
  • The alliance with GSK in osteoarthritis also serves as a strong validation of Galapagos s internal drug discovery programmes in bone and joint diseases. (
  • The last several years has seen an explosion in interest and opportunity for the discovery of new drugs for neglected tropical diseases (NTDs), such as sleeping sickness, malaria, Chagas disease, leishmaniasis, lymphatic filariasis, and schistosomiasis. (
  • I believe that most people who work in NTD drug discovery do so because they truly are looking to cure these diseases of the poor. (
  • The idea that the effect of a drug in the human body is mediated by specific interactions of the drug molecule with biological macromolecules, ( proteins or nucleic acids in most cases) led scientists to the conclusion that individual chemicals are required for the biological activity of the drug. (
  • We are also proud to foster the next generation of drug discovery scientists. (
  • In combination with the information on the drug responses, the list of genetic variations Pommier's team assembled will let scientists take their analyses a step further, he said. (
  • Scientists may use computers to mimic how a potential drug interacts with its target. (
  • The UC San Diego scientists harvested a set of genes predicted to encode a natural product from ocean bacteria, then used the synthetic biology technology to identify and test a totally new antibiotic - taromycin A - found to be effective in fighting drug-resistant MRSA. (
  • GRIDP, which was jointly developed by OSC and GRI scientists and programming experts, mirrors the discovery workflow and leads users through tasks such as protein model preparation and evaluation, binding site prediction, ligand preparation and docking/scoring, protein:ligand energy calculations, and chemical property analysis such as Lipinski's rules and distribution/absorption. (
  • Scientists, executives, and equipment suppliers visit Drug Discovery Online each day to check for news, look for jobs, learn about new products, find out what their competitors are up to, and participate in our discussion forums. (
  • The modules are different, complementary lenses on a core central repository of knowledge from millions of medical articles, abstracts, patents, drugs, conditions and genes/proteins. (
  • This allows it, on a realistic timescale, to model the interactions between drugs and proteins in the body. (
  • As new proteins are identified and their activities determined through functional genomics, each will represent a potential new target for drug therapy. (
  • However, the discovery of the SAMLPs removes this barrier and opens up access to membrane proteins - this has exciting clinical implications as it may enable drug discovery on receptors that are currently too difficult to produce or study by current methods. (
  • PQB plans to sift through large chemical libraries to identify small molecules that exhibit the properties a drug would need to change the course of disease. (
  • Supporting this seemingly radical conjecture, a 2011 paper in Nature Reviews Drug Discovery reported that between 1999 and 2008, more FDA-approved first-in-class small molecules were derived from phenotypic screening (an empiric approach) than from insight-oriented, target-based drug discovery. (
  • A staggering number of potential drug-like molecules are known to exist. (
  • For a drug to stay in the body and not be seen as foreign by the immune system, Majewska says, it needs to possess a specific chain of natural sugar molecules called glycans. (
  • Our innovative platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. (
  • This program will fund clinical studies to measure the safety and tolerability of new drugs for Alzheimer's or other forms of dementia, as well of proof of efficacy studies with biomarker or cognitive outcomes. (
  • The 21 Century Cures Act encourages the Food and Drug Administration to consider "real-world evidence" in its regulation of the safety and efficacy of drugs and devices. (
  • The rat being bigger in size, is the preferred model system for studying drug metabolism and pharmacokinetics. (
  • Nature Reviews Drug Discovery has full responsibility for all editorial content, including NatureVideo content. (
  • By fusing the power of AI with the discovery experience of seasoned drug hunters, we are the first company to automate drug design, surpassing conventional approaches. (
  • Whether for civilian or military populations,the fact remains that insecticide tolerant mosquitoes, drug resistant parasites and lack of effective vaccines necessitate new approaches to combating this scourge. (
  • Combinatorial drug treatment strategies perturb biological networks synergistically to achieve therapeutic effects and represent major opportunities to develop advanced treatments across a variety of human disease areas. (
  • However, the discovery of new combinatorial treatments is challenged by the sheer scale of combinatorial chemical space. (
  • Since 2001 he has split his time between Vernalis (fragment and structure based drug discovery) and York (fragment methods for chemical biology and industrial biotechnology). (
  • current topics in biotechnology and drug discovery. (
  • Please see here for more information on WDD and to learn how Pfizer and IBM are working together to advance drug discovery in 2017 and beyond. (
  • This conference will bring together key opinion leaders and senior industry experts to discuss the latest developments in drug discovery strategies. (
  • Antimicrobial drug discovery: emerging strategies. (
  • In 2004, the Drug Discovery Today journal series expanded with the launch of four online-only review journals: Drug Discovery Today: Disease Mechanisms, Drug Discovery Today: Disease Models, Drug Discovery Today: Therapeutic Strategies, and Drug Discovery Today: Technologies. (
  • With 16 drugs currently undergoing clinical trials, Purdue is among the top institutions in the United States for drug discovery. (
  • Mark M. Awad, MD, PhD, from the Dana-Farber Cancer Institute in Boston, Massachusetts, reported that among 30 patients with NSCLC or CRC bearing the KRAS G12C mutation who had disease progression while being treated with adagrasib in clinical trials, investigators found multiple on-target KRAS alterations and off-target bypass mechanisms of acquired resistance to the drug. (
  • Clinical trials and other aspects of drug discovery. (
  • Healthcare database analyses (claims, electronic health records) have been identified by various regulatory initiatives, including the 21 Century Cures Act and Prescription Drug User Fee Act ("PDUFA"), as useful supplements to randomized clinical trials to generate evidence on the effectiveness, harm, and value of medical products in routine care. (
  • More than 90 percent of candidate cancer drugs fail in late stage clinical trials, costing hundreds of millions of dollars," said Vito Quaranta, M.D., director of the Quantitative Systems Biology Center at Vanderbilt. (
  • Lectures describe the overall journey from concept to clinic in broad terms, providing a very introductory exposure to market analysis and target selection, lead discovery and lead optimisation, clinical trials and the NDA to launch. (
  • While most companies would have buried a failed drug, Immunex resurrected Enbrel by testing it in clinical trials with rheumatoid arthritis patients. (
  • Watson for Drug Discovery delivers a cognitive platform and natural language processing trained in the life sciences domain. (
  • Watson for Drug Discovery is cloud-based. (
  • Watson for Drug Discovery helps predict or define relationships among them through the various modules. (
  • Watson for Drug Discovery uses KnIT technology to automatically generate hypotheses from scientific literature and patents. (
  • This is in response to observations that early stages of drug discovery have not been positively impacted by technologies that have delivered significant efficiencies to other fields. (
  • This figure summarizes the active stages of drug discovery at Purdue. (
  • Without a doubt, these efforts have been enhanced by the clear description of targeted product profiles, and public sharing of data, primarily from the earliest stages of drug discovery. (
  • Furthermore, the growing number of drug discovery projects, coupled to their rapid progression through various stages of drug discovery, is expected to continue to create an increasing demand for computational services. (
  • The study provides an in-depth analysis, highlighting the capabilities of a diverse set of companies that offer such services across different stages of drug discovery, such as target identification, target validation, hit generation, hit-to-lead and lead optimization. (
  • In fact, many drugs bind to G-protein coupled receptors, and in mammalian cells, this test could show if they act as agonists (turning the signal on) or antagonists (blocking the signal). (
  • 9 . The apparatus of claim 1 , wherein the target species comprise new drugs for testing binding ability to the receptors on the sensor. (
  • Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. (
  • He was not, however, interested in becoming a physician and chose instead to study the origin of disease without being involved in the experimental side of drug design and discovery. (
  • QM Implementation in Drug Design: Does It Really Help? (
  • This book will be useful for people working in all disciplines associated with drug discovery in academia or industry, as well as postgraduate students who may be working in the design of allosteric modulators. (
  • Other companies are using the technology to mine and query historical information and results to better predict clinical design pitfalls, as well as to facilitate more effective targeting of drugs for specific disease categories. (
  • Here, we report a high-throughput system for nanoliter-scale phenotypic screening that formulates a chemical library in nanoliter droplet emulsions and automates the construction of chemical combinations en masse using parallel droplet processing. (
  • In vivo high-throughput antimicrobial discovery screens utilizing Caenorhabditis elegans as an alternative host. (
  • Successful assay formats are being made available to academic and commercial organizations for use in high-throughput screening programs that we hope will yield drugs useful in treating human cancers. (
  • NewsA new special issue of SLAS Discovery reflects examples of the recent groundswell of creative new applications for high-throughput flow cytometry (HTFC) in drug discovery. (
  • MecRx and CSIRO have now joined forces with the world-leading Peter MacCallum Cancer Centre to develop and test a promising drug lead for inhibiting the biological target cMyc - a key driver of destructive cell mutation in many cancers. (
  • Lam will focus on building computational models to better understand how immuno-oncology drugs work in the body. (
  • Alzheimer's Society is continuing to seek applications that identify and test drug treatments for Alzheimer's disease and other forms of dementia. (
  • Various polyamine-containing drugs are described that can be used in chemotherapy, and as treatments for infections including trypanosomiasis, leishmaniasis and malaria. (
  • Although atherosclerosis is the leading cause of death in the so-called affluent societies, there is presently no drug in our pharmacologic armamentarium against disease to either prevent or reverse this insidious killer and debilitant of human lives. (
  • We found a range of drugs not previously indicated for infectious disease that synergize with antibiotics. (
  • The second way to approach drug discovery is mechanistically: figure out the cause of a disease, and use this knowledge to shape treatment. (
  • The patients all had initial responses to the drug but then experienced disease progression. (
  • We are now funding a portfolio of studies that look at the preclinical identification, and early and late phase testing of drugs for Alzheimer's disease and vascular dementia. (
  • In this Phase I proposal, Agave BioSystems proposes to develop a validated protocol for the isolation of shikimate pathway genes from P. falciparum, the causative agent of malaria.The success of this approach will allow isolation of other metabolic genes of interest, extending the number of enzymes that can be targeted for drug discovery efforts to effectively combat this global disease. (
  • The most downloaded articles from Drug Discovery Today: Disease Models in the last 90 days. (
  • Recently published articles from Drug Discovery Today: Disease Models. (
  • This is the first book to provide a comprehensive description of polyamine drug discovery, and the utility of polyamine analogues in the treatment of disease. (
  • Discuss parameters for harmonized assay cascades that will be most directive towards the targeted product profiles advanced by MMV, DNDi, and others for new drugs for NTDs. (
  • Through this webinar, which is sponsored by Horizon Discovery , participants will gain a better understanding of the benefit of rat models versus mouse models in functional studies on metabolic pathways. (
  • The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D. (
  • Dr. Woster also maintains a program in antiparasitic drug discovery with a particular emphasis on malaria and trypanosomiasis. (
  • Since 2011 our Drug Discovery programme has focused on repurposing and repositioning of existing drugs. (
  • It has progressed three of these into drug discovery and has initiated a hit-to-lead programme on its most advanced target. (
  • We want to create as many small molecule drug leads as possible," says Shahar Keinan, PhD, CEO and co-founder, Polaris Quantum Biotech (PQB), "[by] combining quantum computing, artificial intelligence (AI), and precision medicine. (
  • The algorithm - partly devised by Dr James Kermode from Warwick's School of Engineering - can accurately predict the interactions between a protein and a drug molecule based on a handful of reference experiments or simulations. (
  • The use of multiple drugs in combination might improve desired functional outcomes while reducing toxicity and overcoming drug resistance. (
  • Hopes for a new category of agents recently hailed as " a triumph of drug discovery " have been dimmed somewhat by new data showing many types of acquired resistance. (
  • In two patients, NSCLC underwent histologic transformation from adenocarcinoma at baseline to squamous cell carcinoma at the time of acquired resistance to the drug. (
  • CSIRO and the Victorian government were crucial in getting our technology off the ground - without their funding support and expertise the idea would never have been tested and the huge potential our platform offers for new drug discovery would have gone unrealised. (
  • Although cytostatic drugs may initially have promising therapeutic effects, they may leave tumor cells alive that then have the potential to cause the cancer to recur. (
  • Even then, few potential drugs ever get to the clinical trial stage due to toxicity, poor absorption or distribution into tissues, or a host of other problems. (
  • The technique has the potential to unlock the drug discovery potential of countless new and mysterious microbes," Nizet concluded. (
  • LabRoots is the leading scientific social networking website, which provides daily scientific trending news and science-themed apparel, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. (
  • Learn how ATCC uses CRISPR technology to create precisely gene-edited isogenic cell models for drug screening applications. (
  • Gain insight into how CRISPR cas9 and PROTACs are being utilised to discover new drugs. (
  • How can protein-protein interactions become the target of a drug discovery effort? (
  • Once the starting point of a drug discovery campaign has been identified, there are a number of key considerations for the lead optimisation phase of drug discovery. (